var docs;if (!docs) docs =[]; docs["95"]={"9500":"<p><b>Title</b> Gefitinib / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Gefitinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer gefitinib at least 6 hours before or after administration of an antacid, and closely monitor clinical response to gefitinib.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Concurrent use of ranitidine and sodium bicarbonate (to achieve and maintain gastric pH above pH 5.0) was associated with an average 44% decrease in gefitinib AUC.<sup>1,2</sup> Gefitinib labeling cautions that concurrent use of drugs that cause sustained elevations in gastric pH (including antacids) may decrease gefitinib plasma concentrations, potentially reducing clinical efficacy.<sup>1,2</sup><br><br>The mechanism for this possible interaction is not certain, but gefitinib aqueous solubility has been shown to decline with increases in gastric pH, particularly as pH increases between pH 4.0 and pH 6.0.<sup>1,2</sup> This could decrease the extent of gefitinib absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Iressa (gefitinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July 2015.</p>\n<p>2. Iressa (gefitinib) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc.; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9501":"<p><b>Title</b> Mycophenolate / Telmisartan</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Telmisartan may decrease the serum concentration of Mycophenolate. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a study of renal transplant participants (N = 40), 30 patients with proteinuria or hypertension were randomly assigned to receive valsartan (80 mg daily), telmisartan (40 mg daily), or candesartan (8 mg daily) for a minimum of 6 months.<sup>1</sup> The remaining 10 patients served as controls and received no angiotensin-receptor blocker (ARB) therapy. All patients received a background immunosuppressive regimen of tacrolimus, prednisolone, and mycophenolate mofetil (MMF). One year after transplantation, a pharmacokinetic analysis of mycophenolic acid ([MPA]; the active metabolite of MMF) and the inactive MPA glucuronide (MPAG) was conducted. Compared with controls, patients who received telmisartan had a dose-adjusted 12 hour MPA AUC that was 29% lower.<sup>1</sup> The MPA AUCs in the presence of valsartan or candesartan did not differ from controls. The maximum and minimum MPA serum concentrations did not differ between any group and the MPAG AUC was also similar between groups. Of note, the MPA AUC achieved in patients who received telmisartan remained in the proposed (although controversial) therapeutic range despite being lower than the MPA AUC in control patients.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but it has been proposed that telmisartan (but not valsartan or candesartan) may enhance the peroxisome proliferator-activated receptor (PPAR) gamma expression. PPAR gamma is thought to induce UGT1A9, an enzyme responsible for glucuronidation of MPA.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Miura M, Satoh S, Kagaya H, et al. Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. <i>J Clin Pharm Ther</i>. 2009;34(6):683-692. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20175802\">[PubMed 20175802]</a></p>\n<p>2. van Gelder T. Mycophenolate blood level monitoring: recent progress. <i>Am J Transplant</i>. 2009;9(7):1495-1499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19519824\">[PubMed 19519824]</a></p>\n<p>3. CellCept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genetech USA Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9502":"<p><b>Title</b> Riociguat / Doxofylline</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Doxofylline may enhance the hypotensive effect of Riociguat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of riociguat with phosphodiesterase inhibitors, such as doxofylline, is contraindicated.</p> \n<p><b>Discussion</b> According to the riociguat prescribing information, use of single doses of riociguat (0.5 mg and 1 mg, sequential) in 7 patients with PAH who were stable on the phosphodiesterase 5 (PDE5) inhibitor sildenafil (20 mg 3 times/day) was associated with additive hemodynamic effects.<sup>1</sup> Additionally, it is noted that among patients who received riociguat 1-2.5 mg 3 times/day together with sildenafil (20 mg 3 times/day) one death occurred that was deemed possibly related to the combination of riociguat and sildenafil.<sup>1</sup> A greater rate of drug discontinuation was also observed in patients receiving this combination.<br><br>Riociguat works by stimulating soluble guanylate cyclase, which is the receptor for nitric oxide, enhancing the production of cGMP. Similarly, phosphodiesterase inhibitors inhibit the breakdown of cGMP, resulting in additive or synergistic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Adempas (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9503":"<p><b>Title</b> Doxofylline / Caffeine and Caffeine Containing Products</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Doxofylline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients taking doxofylline should avoid the use of caffeine or caffeine containing products.</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> Product labeling for doxofylline states that patients taking doxofylline should not consume food or drink containing caffeine.<sup>1</sup> The exact reason for this warning is not stated, but since doxofylline and caffeine are methylxanthine related products, their combined use may lead to additive or synergistic toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doxofylline tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200101732. Accessed December 15, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9504":"<p><b>Title</b> Doxofylline / Theophylline Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Theophylline Derivatives may enhance the adverse/toxic effect of Doxofylline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of doxofylline and other xanthine derivatives such as theophylline or aminophylline.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Dyphylline, Theophylline</p>\n</div> \n<p><b>Discussion</b> Product labeling for doxofylline states that doxofylline should not be combined with other xanthine derivatives.<sup>1</sup> The exact reason for this warning is not stated, but due to the similar pharmacology of these agents, their combined use may lead to additive or synergistic toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doxofylline tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200101732. Accessed December 15, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9505":"<p><b>Title</b> Doxofylline / Sympathomimetics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased doxofylline or sympathomimetic toxicities (increased heart rate, arrhythmias, etc) if a sympathomimetic is combined with doxofylline.</p>\n<div>\n <p><b>Sympathomimetics Interacting Members</b> Acebrophylline, Albuterol, Amezinium, Aminophylline, Amphetamine, Arformoterol, Armodafinil, Bambuterol, Benzphetamine, Bitter Orange, Caffeine, Cocaine (Topical), Dexmethylphenidate, Dextroamphetamine, Diethylpropion, DOBUTamine, DOPamine, Doxapram, Dyphylline, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), EPINEPHrine (Systemic), Fenoterol, Formoterol, Indacaterol, Isometheptene, Isoproterenol, Kola Nut, Levalbuterol, Levonordefrin, Lisdexamfetamine, Metaproterenol, Metaraminol, Methamphetamine, Methylphenidate, Midodrine, Modafinil, Naphazoline (Nasal), Naphazoline (Ophthalmic), Norepinephrine, Olodaterol, Oxymetazoline (Nasal), Phendimetrazine, Phentermine, Phenylephrine (Nasal), Phenylephrine (Ophthalmic), Phenylephrine (Systemic), Phenylephrine (Topical), Pirbuterol, Propylhexedrine, Pseudoephedrine, Ritodrine, Salmeterol, Terbutaline, Theophylline, Tulobuterol, Vilanterol, Xylometazoline</p>\n</div> \n<p><b>Discussion</b> Product labeling for doxofylline states that the use of ephedrine or other sympathomimetics with doxofylline may result in increased toxicities.<sup>1</sup> Although doxofylline has less cardiac toxicity than other xanthines, such as theophylline, it is not completely devoid of these effects. Concomitant use with sympathomimetics may result in additive or synergistic toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doxofylline tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200101732. Accessed December 15, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9506":"<p><b>Title</b> Doxofylline / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erythromycin (Systemic) may increase the serum concentration of Doxofylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased doxofylline effects/toxicities and consider measuring serum concentrations if combined with erythromycin. A doxofylline dose reduction may be required.</p> \n<p><b>Discussion</b> According to the doxofylline product label, certain drugs may decrease doxofylline metabolism and lead to increased doxofylline concentrations.<sup>1</sup> Specific agents listed include erythromycin, troleandomycin, lincomycin, allopurinol, cimetidine, ranitidine, propranolol, and the influenza vaccine.<sup>1</sup> The mechanism of these potential interactions is not stated and the metabolic routes of elimination for doxofylline have not been established. Many of these listed drugs are inhibitors of CYP3A4 and CYP1A2, enzymes responsible for the elimination of theophylline, a related xanthine compound, and may be the reason for the stated warning. Whether doxofylline metabolism would be affected the same way as that of theophylline in the presence of CYP inhibitors is unknown, but product labeling warns that these drug interactions may occur. No published studies or case reports describe interactions between doxofylline and these drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doxofylline tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200101732. Accessed December 15, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9507":"<p><b>Title</b> Doxofylline / Lincomycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lincomycin may increase the serum concentration of Doxofylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased doxofylline effects/toxicities and consider measuring serum concentrations if combined with lincomycin. A doxofylline dose reduction may be required.</p> \n<p><b>Discussion</b> According to the doxofylline product label, certain drugs may decrease doxofylline metabolism and lead to increased doxofylline concentrations.<sup>1</sup> Specific agents listed include erythromycin, troleandomycin, lincomycin, allopurinol, cimetidine, ranitidine, propranolol, and the influenza vaccine.<sup>1</sup> The mechanism of these potential interactions is not stated and the metabolic routes of elimination for doxofylline have not been established. Many of these listed drugs are inhibitors of CYP3A4 and CYP1A2, enzymes responsible for the elimination of theophylline, a related xanthine compound, and may be the reason for the stated warning. Whether doxofylline metabolism would be affected the same way as that of theophylline in the presence of CYP inhibitors is unknown, but product labeling warns that these drug interactions may occur. No published studies or case reports describe interactions between doxofylline and these drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doxofylline tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200101732. Accessed December 15, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9508":"<p><b>Title</b> Doxofylline / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Allopurinol may increase the serum concentration of Doxofylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased doxofylline effects/toxicities and consider measuring serum concentrations if combined with allopurinol. A doxofylline dose reduction may be required.</p> \n<p><b>Discussion</b> According to the doxofylline product label, certain drugs may decrease doxofylline metabolism and lead to increased doxofylline concentrations.<sup>1</sup> Specific agents listed include erythromycin, troleandomycin, lincomycin, allopurinol, cimetidine, ranitidine, propranolol, and the influenza vaccine.<sup>1</sup> The mechanism of these potential interactions is not stated and the metabolic routes of elimination for doxofylline have not been established. Many of these listed drugs are inhibitors of CYP3A4 and CYP1A2, enzymes responsible for the elimination of theophylline, a related xanthine compound, and may be the reason for the stated warning. Evidence for allopurinol inhibition of these enzymes is very limited,<sup>2</sup> but an interaction between theophylline and allopurinol has been reported.<sup>3,4</sup> Whether doxofylline metabolism would be affected the same way as that of theophylline in the presence of CYP inhibitors is unknown, but product labeling warns that these drug interactions may occur. No published studies or case reports describe interactions between doxofylline and these drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doxofylline tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200101732. Accessed December 15, 2015.</p>\n<p>2. Xu RA, Xu ZS, Hu LF, et al. Effects of repeated allopurinol administration on rat cytochrome P450 activity. <i>Pharmazie</i>. 2013;68(5):365-368. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23802435\">[PubMed 23802435]</a></p>\n<p>3. Barry M, Feely J. Allopurinol influences amiphenazone elimination. <i>Clin Pharmacokinet</i>. 1990;19(2):167-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2379382\">[PubMed 2379382]</a></p>\n<p>4. Manfredi RL, Vesell ES. Inhibition of theophylline metabolism by long-term allopurinol administration. <i>Clin Pharmacol Ther</i>. 1981;29(2):224-229. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7460486\">[PubMed 7460486]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9509":"<p><b>Title</b> Doxofylline / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Doxofylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased doxofylline effects/toxicities and consider measuring serum concentrations if combined with cimetidine. A doxofylline dose reduction may be required.</p> \n<p><b>Discussion</b> According to the doxofylline product label, certain drugs may decrease doxofylline metabolism and lead to increased doxofylline concentrations.<sup>1</sup> Specific agents listed include erythromycin, troleandomycin, lincomycin, allopurinol, cimetidine, ranitidine, propranolol, and the influenza vaccine.<sup>1</sup> The mechanism of these potential interactions is not stated and the metabolic routes of elimination for doxofylline have not been established. Many of these listed drugs are inhibitors of CYP3A4 and CYP1A2, enzymes responsible for the elimination of theophylline, a related xanthine compound, and may be the reason for the stated warning. Whether doxofylline metabolism would be affected the same way as that of theophylline in the presence of CYP inhibitors is unknown, but product labeling warns that these drug interactions may occur. No published studies or case reports describe interactions between doxofylline and these drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doxofylline tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200101732. Accessed December 15, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9510":"<p><b>Title</b> Doxofylline / RaNITIdine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RaNITIdine may increase the serum concentration of Doxofylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased doxofylline effects/toxicities and consider measuring serum concentrations if combined with ranitidine. A doxofylline dose reduction may be required.</p> \n<p><b>Discussion</b> According to the doxofylline product label, certain drugs may decrease doxofylline metabolism and lead to increased doxofylline concentrations.<sup>1</sup> Specific agents listed include erythromycin, troleandomycin, lincomycin, allopurinol, cimetidine, ranitidine, propranolol, and the influenza vaccine.<sup>1</sup> The mechanism of these potential interactions is not stated and the metabolic routes of elimination for doxofylline have not been established. Many of these listed drugs are inhibitors of CYP3A4 and CYP1A2, enzymes responsible for the elimination of theophylline, a related xanthine compound, and may be the reason for the stated warning. Whether doxofylline metabolism would be affected the same way as that of theophylline in the presence of these drugs is unknown, but product labeling warns that these drug interactions may occur. No published studies or case reports describe interactions between doxofylline and these drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doxofylline tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200101732. Accessed December 15, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9511":"<p><b>Title</b> Doxofylline / Propranolol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propranolol may increase the serum concentration of Doxofylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased doxofylline effects/toxicities and consider measuring serum concentrations if combined with propranolol. A doxofylline dose reduction may be required.</p> \n<p><b>Discussion</b> According to the doxofylline product label, certain drugs may decrease doxofylline metabolism and lead to increased doxofylline concentrations.<sup>1</sup> Specific agents listed include erythromycin, troleandomycin, lincomycin, allopurinol, cimetidine, ranitidine, propranolol, and the influenza vaccine.<sup>1</sup> The mechanism of these potential interactions is not stated and the metabolic routes of elimination for doxofylline have not been established. Many of these listed drugs are inhibitors of CYP3A4 and CYP1A2, enzymes responsible for the elimination of theophylline, a related xanthine compound, and may be the reason for the stated warning. Whether doxofylline metabolism would be affected the same way as that of theophylline in the presence of CYP inhibitors is unknown, but product labeling warns that these drug interactions may occur. No published studies or case reports describe interactions between doxofylline and these drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doxofylline tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200101732. Accessed December 15, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9512":"<p><b>Title</b> Doxofylline / Influenza Virus Vaccine (Inactivated)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Influenza Virus Vaccine (Inactivated) may increase the serum concentration of Doxofylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased doxofylline effects/toxicities and consider measuring serum concentrations if combined with the influenza virus vaccine. A doxofylline dose reduction may be required.</p> \n<p><b>Discussion</b> According to the doxofylline product label, certain drugs may decrease doxofylline metabolism and lead to increased doxofylline concentrations.<sup>1</sup> Specific agents listed include erythromycin, troleandomycin, lincomycin, allopurinol, cimetidine, ranitidine, propranolol, and the influenza vaccine.<sup>1</sup> The mechanism of these potential interactions is not stated and the metabolic routes of elimination for doxofylline have not been established. Many of these listed drugs are inhibitors of CYP3A4 and CYP1A2, enzymes responsible for the elimination of theophylline, a related xanthine compound, and may be the reason for the stated warning. The influenza virus vaccine is not considered a CYP enzyme inhibitor and reports have both supported and refuted an interaction between the vaccine and theophylline.<sup>2,3,4</sup> Whether doxofylline metabolism would be affected the same way as that of theophylline in the presence of the influenza virus vaccine is unknown, but product labeling warns that this drug interaction may occur. No published studies or case reports describe interactions between doxofylline and the influenza virus vaccine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doxofylline tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200101732. Accessed December 15, 2015.</p>\n<p>2. Kramer P, McClain CJ. Depression of aminopyrine metabolism by influenza vaccination. <i>N Engl J Med</i>. 1981;305(21):1262-1264. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7290142\">[PubMed 7290142]</a></p>\n<p>3. Renton KW, Gray JD, Hall RI. Decreased elimination of theophylline after influenza vaccination. <i>Can Med Assoc J</i>. 1980;123(4):288-290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7260771\">[PubMed 7260771]</a></p>\n<p>4. Hannan SE, May JJ, Pratt DS, Richtsmeier WJ, Bertino JS Jr. The effect of whole virus influenza vaccination on theophylline pharmacokinetics. <i>Am Rev Respir Dis</i>. 1988;137(4):903-906. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2451459\">[PubMed 2451459]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9513":"<p><b>Title</b> Doxofylline / Fosphenytoin-Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of Doxofylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased effects/therapeutic failure if doxofylline is combined with fosphenytoin or phenytoin. A doxofylline dose increase may be required.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> According to the doxofylline product label, phenytoin may increase doxofylline metabolism and lead to decreased doxofylline concentrations.<sup>1</sup> The mechanism of this potential interaction is not stated and the metabolic routes of elimination for doxofylline have not been established. While an interaction has been reported between phenytoin and theophylline (a related xanthine compound) it is unknown if doxofylline metabolism would be affected the same way in the presence of phenytoin. No published studies or case reports describe interactions between doxofylline and phenytoin or fosphenytoin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doxofylline tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200101732. Accessed December 15, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9514":"<p><b>Title</b> Hexaminolevulinate / BCG (Intravesical)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> BCG (Intravesical) may diminish the diagnostic effect of Hexaminolevulinate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid hexaminolevulinate in patients who have received BCG immunotherapy or intravesical chemotherapy in the past 90 days.</p> \n<p><b>Discussion</b> Prescribing information for hexaminolevulinate lists its use as contraindicated in patients who have received BCG immunotherapy or intravesical chemotherapy within the past 90 days.<sup>1</sup> No reason for the contraindication is stated, but similar recommendations have been given based on the potential for false positive fluorescence from inflammatory tissue.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cysview (hexaminolevulinate) [prescribing information]. Princeton, NJ: GE Healthcare Inc; June 2010.</p>\n<p>2. Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy<i>J Urol</i>. 2004;171(1):135-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14665861\">[PubMed 14665861]</a></p>\n<p>3. Ray ER, Chatterton K, Khan MS, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. <i>BJU Int</i>. 2010;105(6):789-794. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19832725\">[PubMed 19832725]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9515":"<p><b>Title</b> CNS Depressants / Minocycline</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to the intravenous administration of minocycline.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Minocycline may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of enhanced CNS depression when using intravenous (IV) minocycline (which contains 269 mg of magnesium sulfate heptahydrate per 100 mg dose) with a CNS depressant. Dose adjustments of the CNS depressant may be necessary.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Although most low-dose magnesium administration may not be associated with CNS depressant effects, magnesium sulfate (primarily given via IV or epidural routes) has been associated with a reduced need for sedatives, anesthetics, and analgesics in several small clinical trials.<sup>1,2,3</sup> Similarly, published case reports describe patients who have experienced clinically significant CNS depression following the use of magnesium sulfate.<sup>4,5</sup><br><br>Magnesium sulfate prescribing information warns about the potential for additive and excessive CNS depression when used with CNS depressants,<sup>6,7</sup> and product labeling for IV minocycline states that due to the magnesium sulfate heptahydrate contained in the formulation, administration with CNS depressants may lead to serious adverse reactions.<sup>8</sup><br><br>The specific mechanism for this potential interaction is unclear, although both low and high concentrations of magnesium appear to have effects on mood, motor function, and levels of alertness.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sikendar RI, us Samad B, Ali S, Memon MI. Post traumatic tetanus and role of magnesium sulphate. <i>J Ayub Med Coll Abbottabad</i>. 2009;21(2):132-135. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20524490\">[PubMed 20524490]</a></p>\n<p>2. Khafagy HF, Osman ES, Naguib AF. Effects of different dose regimens of magnesium on pharmacodynamics and anesthetic requirements of balanced general anesthesia. <i>J Egypt Soc Parasitol</i>. 2007;37(2):469-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17985581\">[PubMed 17985581]</a></p>\n<p>3. Bilir A, Gulec S, Erkan A, Ozcelik A. Epidural magnesium reduces postoperative analgesic requirement. <i>Br J Anaesth</i>. 2007;98(4):519-523. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17324976\">[PubMed 17324976]</a></p>\n<p>4. McDonnell NJ, Muchatuta NA, Paech MJ. Acute magnesium toxicity in an obstetric patient undergoing general anaesthesia for caesarean delivery. <i>Int J Obstet Anesth</i>. 2010;19(2):226-231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20219345\">[PubMed 20219345]</a></p>\n<p>5. Robins K, Lyons G. Opioid-related narcosis in a woman with myopathy receiving magnesium. <i>Int J Obstet Anesth</i>. 2007;16(4):367-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17643282\">[PubMed 17643282]</a></p>\n<p>6. Magnesium sulfate [prescribing information]. Schaumburg, IL: APP Pharmaceuticals LLC; January 2008.</p>\n<p>7. Magnesium sulfate [prescribing information]. Lake Forest, IL: Hospira Inc; November 2009.</p>\n<p>8. Minocin (minocycline) injection [prescribing information]. Parsippany, NJ: The Medicines Company; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9516":"<p><b>Title</b> Neuromuscular-Blocking Agents / Minocycline</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to the intravenous administration of minocycline.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Minocycline may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for enhanced or prolonged effects of neuromuscular blocking agents in patients receiving intravenous (IV) minocycline (which contains 269 mg of magnesium sulfate heptahydrate per 100 mg dose). High-risk patients include those with elevated serum magnesium concentrations or renal impairment.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine, Vecuronium</p>\n</div> \n<p><b>Discussion</b> Numerous case reports and clinical studies have demonstrated enhanced neuromuscular blockade in patients receiving magnesium in combination with neuromuscular blocking agents, including atracurium, cisatracurium, succinylcholine, pancuronium, vecuronium, and rocuronium.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24</sup> Enhanced effects have included more rapid onset, greater duration of action, and lower dose requirements of the neuromuscular blocking agent. Two studies have also shown a return of neuromuscular blockade when parenteral magnesium was administered shortly after recovery.<sup>7,18</sup> Enhanced neuromuscular blocking effects have been most often seen in hypermagnesemic patients and those treated with parenteral magnesium. Two studies showed no enhancement of succinylcholine induced neuromuscular blockade with magnesium supplementation.<sup>25,26</sup> <br><br>Product labeling for IV minocycline states that due to the magnesium sulfate heptahydrate contained in the formulation, administration with neuromuscular blocking agents may lead to serious adverse reactions.<sup>27</sup><br><br>Magnesium possesses some weak neuromuscular blocking activity. This is likely additive with neuromuscular-blocking agents, and other medications that possess such properties (eg, aminoglycoside antibiotics). Specific dose adjustment guidelines are lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sinatra RS, Philip BK, Naulty JS,Ostheimer GW. Prolonged neuromuscular blockade with vecuronium in a patient treated with magnesium sulphate. <i>Anesth Analg</i>. 1985;64(12):1220-1222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2865911\">[PubMed 2865911]</a></p>\n<p>2. Ghoneim MM, Long JP. The interaction between magnesium and other neuromuscular-blocking agents. <i>Anesthesiology</i>. 1970;32(1):23-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5460601\">[PubMed 5460601]</a></p>\n<p>3. Ip-Yam C, Allsop E. Abnormal response to suxamethonium in a patient receiving magnesium therapy. <i>Anaesthesia</i>. 1994;49(4):355-356. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8179157\">[PubMed 8179157]</a></p>\n<p>4. Baraka A, Yazigi A. Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. <i>Anesthesiology</i>. 1987;67(5):806-808. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2890318\">[PubMed 2890318]</a></p>\n<p>5. Gaiser RR, Seem EH. Use of rocuronium in a pregnant patient with an open eye injury, receiving magnesium medication, for preterm labour. <i>Br J Anaesth</i>. 1996;77(5):669-671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8957990\">[PubMed 8957990]</a></p>\n<p>6. Morris R, Giesecke AH. Potentiation of muscle relaxants by magnesium sulfate therapy in toxemia of pregnancy. <i>South Med J</i>. 1968;61:25.</p>\n<p>7. Fuchs-Buder T, Tassonyi E. Magnesium sulphate enhances residual neuromuscular block induced by vecuronium. <i>Br J Anaesth</i>. 1996;76(4):565-566. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8652332\">[PubMed 8652332]</a></p>\n<p>8. Kussman B, Shorten G, Uppington J, Comunale ME. Administration of magnesium sulphate before rocuronium: effects on speed of onset and duration of neuromuscular block. <i>Br J Anaesth</i>. 1997;79(1):122-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9301400\">[PubMed 9301400]</a></p>\n<p>9. Gupta K, Vohra V, Sood J. The role of magnesium as an adjuvant during general anaesthesia. <i>Anaesthesia</i>. 2006;61(11):1058-1063. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17042843\">[PubMed 17042843]</a></p>\n<p>10. Yoshida A, Itoh Y, Nagaya K. Prolonged relaxant effects of vecuronium in patients with deliberate hypermagnesemia: time for caution in cesarean section. <i>J Anesth</i>. 2006;20(1):33-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16421674\">[PubMed 16421674]</a></p>\n<p>11. Pinard AM, Donati F, Martineau R, Denault AY, Taillefer J, Carrier M. Magnesium potentiates neuromuscular blockade with cisatracurium during cardiac surgery. <i>Can J Anaesth</i>. 2003;50(2):172-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12560310\">[PubMed 12560310]</a></p>\n<p>12. Kwan WF, Lee C, Chen BJ. A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient. <i>J Clin Anesth</i>. 1996;8(5):392-397. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8832451\">[PubMed 8832451]</a></p>\n<p>13. Ryu JH, Kang MH, Park KS, Do SH. Effects of magnesium sulphate on intraoperative anaesthetic requirements and postoperative analgesia in gynaecology patients receiving total intravenous anaesthesia. <i>Br J Anaesth</i>. 2008;100(3):397-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18276652\">[PubMed 18276652]</a></p>\n<p>14. Na HS, Lee JH, Hwang JY, et al. Effects of magnesium sulphate on intraoperative neuromuscular blocking agent requirements and postoperative analgesia in children with cerebral palsy. <i>Br J Anaesth</i>. 2010;104(3):344-350. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20042475\">[PubMed 20042475]</a></p>\n<p>15. Telci L, Esen F, Akcora D, Erden T, Canbolat AT, Akpir K. Evaluation of effects of magnesium sulphate in reducing intraoperative anaesthetic requirements. <i>Br J Anaesth</i>. 2002;89(4):591-598. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12393361\">[PubMed 12393361]</a></p>\n<p>16. Aldrete JA, Zahler A, Aikawa JK. Prevention of succinylcholine-induced hyperkalaemia by magnesium sulfate. <i>Can Anaesth Soc J</i>. 1970;17(5):477-484. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5506078\">[PubMed 5506078]</a></p>\n<p>17. Fuchs-Buder T, Wilder-Smith OH, Borgeat A, Tassonyi E. Interaction of magnesium sulphate with vecuronium-induced neuromuscular block. <i>Br J Anaesth</i>. 1995;74(4):405-409.<a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7734259\">[PubMed 7734259]</a></p>\n<p>18. Fawcett WJ, Stone JP. Recurarization in the recovery room following the use of magnesium sulphate. <i>Br J Anaesth</i>. 2003;91(3):435-438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12925489\">[PubMed 12925489]</a></p>\n<p>19. De Vore JS, Asrani R. Magnesium sulfate prevents succinylcholine-induced fasciculations in toxemic parturients. <i>Anesthesiology</i>. 1980;52(1):76-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7352649\">[PubMed 7352649]</a></p>\n<p>20. Lee DH, Kwon IC. Magnesium sulphate has beneficial effects as an adjuvant during general anaesthesia for caesarean section. <i>Br J Anaesth</i>. 2009;103(6):861-866. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19783538\">[PubMed 19783538]</a></p>\n<p>21. Cizmeci P, Ozkose Z. Magnesium sulphate as an adjuvant to total intravenous anesthesia in septorhinoplasty: a randomized controlled study. <i>Aesthetic Plast Surg</i>. 2007;31(2):167-173. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17437152\">[PubMed 17437152]</a></p>\n<p>22. Olivieri L, Plourde G. Prolonged (more than ten hours) neuromuscular blockade after cardiac surgery: report of two cases. <i>Can J Anaesth</i>. 2005;52(1):88-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15625263\">[PubMed 15625263]</a></p>\n<p>23. Khafagy HF, Osman ES, Naguib AF. Effects of different dose regimens of magnesium on pharmacodynamics and anesthetic requirements of balanced general anesthesia. <i>J Egypt Soc Parasitol</i>. 2007;37(2):469-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17985581\">[PubMed 17985581]</a></p>\n<p>24. James MF, Schenk PA, van der Veen BW. Priming of pancuronium with magnesium. <i>Br J Anaesth</i>. 1991;66(2):247-249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1817630\">[PubMed 1817630]</a></p>\n<p>25. Stacey MR, Barclay K, Asai T, Vaughan RS. Effects of magnesium sulphate on suxamethonium-induced complications during rapid-sequence induction of anaesthesia. <i>Anaesthesia</i>. 1995;50(11):933-936. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8678246\">[PubMed 8678246]</a></p>\n<p>26. James MF, Cork RC, Dennett JE. Succinylcholine pretreatment with magnesium sulfate. <i>Anesth Analg</i>. 1986;65(4):373-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3513667\">[PubMed 3513667]</a></p>\n<p>27. Minocin (minocycline) injection [prescribing information]. Parsippany, NJ: The Medicines Company; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9517":"<p><b>Title</b> Valproate Products / Acarbose</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acarbose may decrease the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased serum valproate concentrations/therapeutic effects if administered concomitant with acarbose. The effect of separating the doses of these agents is unknown.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Case report. Serum valproate concentrations were decreased by 40% in a 10-year-old patient following the addition of acarbose to the medication regimen. Rechallenge demonstrated the same result.<sup>1</sup> The mechanism of this interaction is unclear. Acarbose may inhibit the absorption of valproate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Serrano JS, et al, “May Acarbose Impair Valproate Bioavailability?” <i>Meth Find Exp Clin Pharmacol</i>, 1996, 18(Suppl C):98.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9518":"<p><b>Title</b> Valproate Products / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may increase the absorption of Valproate Products. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> A single study demonstrated a 3% to 28% increase in valproate AUC when valproic acid was coadministered with aluminum/magnesium hydroxide.<sup>1</sup> The same study showed no effect from coadministration with magnesium trisilicate or calcium carbonate. The mechanism of this interaction is unknown. No adverse clinical effects were noted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. May CA, Garnett WR, Small RE, et al, “Effects of Three Antacids on the Bioavailability of Valproic Acid,” <i>Clin Pharm</i>, 1982, 1(3):244-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6821035\">[PubMed 6821035]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9519":"<p><b>Title</b> Valproate Products / Carbapenems</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Carbapenems may decrease the serum concentration of Valproate Products. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of carbapenem antibiotics with valproate products is generally not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication, such as benzodiazepines or renally cleared antiepileptic medications. Close monitoring of valproate concentrations is necessary whenever using a carbapenem with valproic acid and derivatives (particularly when starting or stopping the carbapenem). Valproate concentrations may decrease significantly with addition of a carbapenem, and increased doses may not adequately compensate for the interaction. Valproate concentrations generally return towards normal shortly after discontinuation of the carbapenem.</p>\n<div>\n <p><b>Carbapenems Interacting Members</b> Doripenem, Ertapenem, Imipenem, Meropenem</p>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Retrospective studies of patients receiving valproate products have reported that the average valproic acid serum concentration decreased after the addition of meropenem (82% to 67%), ertapenem (72% to 68%), and imipenem (51%).<sup>1,2,3,4</sup> Some studies also reported an increase in seizures during combination therapy.<sup>1,2</sup> Several case reports and case series also describe significant decreases in serum valproate concentrations (usually to subtherapeutic values) following the initiation of therapy with a carbapenem antibiotic.<sup>5,6,7,8,9,10,11,12</sup> In these cases, serum valproate concentrations decreased rapidly (often within days) and substantially (up to 90%) following carbapenem initiation. Valproate concentrations generally returned to normal in a similarly rapid fashion, though one case study reports persistent (up to two weeks) reduction of valproate concentrations after discontinuation of meropenem.<sup>12</sup> Seizures accompanied some of the pharmacokinetic changes. <br><br>The mean valproate AUC was reduced by an average of 63% with concurrent doripenem in a study of 23 healthy volunteers who received doripenem (500 mg every 8 hours for 4 doses) plus valproic acid (500 mg every 12 hours for 7 days).<sup>13</sup> Valproate maximum serum concentrations (Cmax) and minimum serum concentrations (Cmin) were similarly decreased (by an average of 45% and 78%, respectively) with concurrent doripenem. Concentrations of the valproate glucuronide metabolite were increased with doripenem. <br><br>The mechanism(s) responsible for this observed interaction is unclear, but decreased enteric hydrolysis of the valproate glucuronide (i.e., decreased enterohepatic recirculation) is thought to be principally responsible.<sup>13,14,15,16,17,18</sup> Other possible mechanisms include decreased intestinal absorption,<sup>19,20</sup> decreased hepatic hydrolysis of the valproate glucuronide,<sup>21</sup> increased valproate glucuronidation,<sup>21,22</sup> increased renal clearance of valproate glucuronide,<sup>18,22</sup> and increased distribution of valproate into red blood cells.<sup>11</sup><br><br>Of note, one case study describes coadministration of meropenem and valproic acid for 13 days with no apparent interaction in a cirrhotic patient.<sup>23</sup> The reason for an absent interaction in this case is uncertain, though it is possible that impaired hepatic glucuronidation and biliary drug secretion due to the patient's advanced liver disease led to decreased valproic acid clearance, countering the effects of the carbapenem.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Huang CR, Lin CH, Hsiao SC, et al. Drug interaction between valproic acid and carbapenems in patients with epileptic seizures. <i>Kaohsiung J Med Sci</i>. 2017;33(3):130-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28254115\">[PubMed 28254115]</a></p>\n<p>2. Miranda Herrero MC, Alcaraz Romero AJ, Escudero Vilaplana V, et al. Pharmacological interaction between valproic acid and carbapenem: what about levels in pediatrics? <i>Eur J Paediatr Neurol</i>. 2015;19(2):155-161. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25578527\">[PubMed 25578527]</a></p>\n<p>3. Haroutiunian S, Ratz Y, Rabinovich B, Adam M, Hoffman A. Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study. <i>J Clin Pharmacol</i>. 2009;49(11):1363-1369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19773524\">[PubMed 19773524]</a></p>\n<p>4. Wu CC, Pai TY, Hsiao FY, Shen LJ, Wu FL. The effect of different carbapenem antibiotics (ertapenem, imipenem/cilastatin, and meropenem) on serum valproic acid concentrations. <i>Ther Drug Monit</i>. 2016;38(5):587-592. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27322166\">[PubMed 27322166]</a></p>\n<p>5. Nagai K, Shimizu T, Togo A, et al. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. <i>J Antimicrob Chemother</i>. 1997;39(2):295-296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9069562\">[PubMed 9069562]</a></p>\n<p>6. Yamagata T, Momoi MY, Murai K, et al. Panipenem-betamipron and decreases in serum valproic acid concentration. <i>Ther Drug Monit</i>. 1998;20(4):396-400. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9712464\">[PubMed 9712464]</a></p>\n<p>7. De Turck BJ, Diltoer MW, Cornelis PJ, et al. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. <i>J Antimicrob Chemother</i>. 1998;42(4):563-564. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9818768\">[PubMed 9818768]</a></p>\n<p>8. Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of valproic acid. <i>Pediatr Neurol</i>. 2004;31(3):232-234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15351028\">[PubMed 15351028]</a></p>\n<p>9. Coves-Orts FJ, Borras-Blasco J, Navarro-Ruiz A, Murcia-Lopez A, Palacios-Ortega F. Acute seizures due to a probable interaction between valproic acid and meropenem. <i>Ann Pharmacother</i>. 2005;39(3):533-537. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15701769\">[PubMed 15701769]</a></p>\n<p>10. Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. <i>Pharmacotherapy</i>. 2007;27(8):1202-1205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17655519\">[PubMed 17655519]</a></p>\n<p>11. Park MK, Lim KS, Kim TE, et al. Reduced valproic acid serum concentrations due to drug interactions with carbapenem antibiotics: overview of 6 cases. <i>Ther Drug Monit</i>. 2012;34(5): 599-603. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22929406\">[PubMed 22929406]</a></p>\n<p>12. Taha FA, Hammond DN, Sheth RD, Firas T, David H, Raj S. Seizures from valproate - carbapenem interaction. <i>Pediatr Neurol</i>. 2013;49(4):279-281. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23932807\">[PubMed 23932807]</a></p>\n<p>13. Doribax (doripenem) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals Inc; May, 2009.</p>\n<p>14. Primaxin I.V. (imipenem and cilastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August, 2009.</p>\n<p>15. Invanz (ertapenem) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; December, 2009.</p>\n<p>16. Merrem I.V. (meropenem) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July, 2009.</p>\n<p>17. Kojima S, Nadai M, Kitaichi K, Wang L, Nabeshima T, Hasegawa T. Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats. <i>Antimicrob Agents Chemother</i>. 1998;42(12):3136-3140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9835504\">[PubMed 9835504]</a></p>\n<p>18. Yokogawa K, Iwashita S, Kubota A, et al. Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. <i>Pharm Res</i>. 2001;18(9):1320-1326. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11683247\">[PubMed 11683247]</a></p>\n<p>19. Torii M, Takiguchi Y, Saito F, Izumi M, Yokota M. Inhibition by carbapenem antibiotic imipenem of intestinal absorption of valproic acid in rats. <i>J Pharm Pharmacol</i>. 2001;53(6):823-829. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11428658\">[PubMed 11428658]</a></p>\n<p>20. Torii M, Takiguchi Y, Izumi M, Fukushima T, Yokota M. Carbapenem antibiotics inhibit valproic acid transport in caco-2 cell monolayers. <i>Int J Pharm</i>. 2002;233(1-2):253-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11897429\">[PubMed 11897429]</a></p>\n<p>21. Nakajima Y, Mizobuchi M, Nakamura M, et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. <i>Drug Metab Dispos</i>. 2004;32(12):1383-1391. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15345660\">[PubMed 15345660]</a></p>\n<p>22. Yamamura N, Imura K, Naganuma H, et al. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats. <i>Drug Metab Dispos</i>. 1999;27(6):724-730. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10348803\">[PubMed 10348803]</a></p>\n<p>23. Spriet I, Willems L. No interaction between valproate and meropenem in a cirrhotic patient. <i>Ann Pharmacother</i>. 2011;45(9):1167-1168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21811003\">[PubMed 21811003]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9520":"<p><b>Title</b> Valproate Products / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Macrolide Antibiotics may increase the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Consider selecting a noninteracting macrolide. Monitor for increased toxic effects of valproate if an interacting macrolide antibiotic is initiated/dose increased, or decreased effects if an interacting macrolide is discontinued/dose decreased.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Clarithromycin, Erythromycin (Systemic), Telithromycin<br><b>Exceptions</b> Azithromycin (Systemic), Fidaxomicin, Roxithromycin, Spiramycin</p>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> The serum valproate concentration increased nearly threefold within 1 week of starting erythromycin (250 mg 4 times/day) in a patient taking valproic acid.<sup>1</sup> [<b>NOTE:</b> The baseline concentration was determined 2 months prior to erythromycin therapy.] The increased valproate concentrations were accompanied by symptoms of toxicity including problems with gait, speech, and concentration. Recovery occurred following withdrawal of both drugs. The mechanism of this presumed interaction is unknown, but might be related to macrolide inhibition of CYP isoenzymes, and subsequent inhibition of valproate metabolism. Telitrhromycin, a ketolide antibiotic, is a strong CYP3A4 inhibitor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Redington K, Wells C, and Petito F, “Erythromycin and Valproate Interaction,” <i>Ann Intern Med</i>, 1992, 116(10):877-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1567109\">[PubMed 1567109]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9521":"<p><b>Title</b> Tricyclic Antidepressants / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may increase the serum concentration of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patient for signs of tricyclic toxicity. It may be reasonable to monitor tricyclic serum concentrations, particularly when initiating, changing doses or discontinuing valproate therapy. Dose reductions (of tricyclic agent) have been effective in managing this interaction.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Case studies note substantial elevations of amitriptyline, nortriptyline, and clomipramine serum concentrations with concomitant valproic acid or derivative therapy. In a study of 15 healthy subjects, the AUCs of amitriptyline (after a single 50 mg dose) and the nortriptyline metabolite were increased 30% and 55%, respectively, with concurrent semisodium valproate (500 mg twice daily).<sup>1</sup> Another study in 10 patients noted 50% and 65% increases in the serum concentrations of amitriptyline and nortriptyline, respectively, with concomitant valpromide administration (600 mg daily x 10 days).<sup>2</sup> In another case, neurologic toxicity (delirium or tremors) was evident 1 week after initiating valproic acid (750-1000 mg/day) in two patients already receiving nortriptyline.<sup>3</sup> In one of these patients, a 3-fold elevation in nortriptyline levels was observed after valproate started. Finally, a report associated the occurrence of numbness and sleep distrubance in a patient with elevated clomipramine levels purportedly caused by 1-1.4 g/day of valproate.<sup>4</sup> The mechanism(s) of these interactions has(have) not been determined, though authors have speculated that a reduction in tricyclic metabolism may account for the observations. The manufacturer of Depakote does acknowledge this concern with amitriptyline/nortriptyline and recommends drug level monitoring and possible dose reduction of the tricyclic if used concurrently with valproate.<sup>5</sup> Whether this phenomenon extends to other members of the tricyclic class of antidepressants is unknown. Considering the lack of additional case report publications and given the long history and frequency of use of these agents, the likelihood of interaction with other tricyclic antidepressants seems low but cannot be discounted. Thus, it would seem prudent to monitor patients carefully when employing these two classes of drugs concurrently.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wong SL, Cavanaugh J, Shi H, et al, “Effects of Divalproex Sodium on Amitriptyline and Nortriptyline Pharmacokinetics,” <i>Clin Pharmacol Ther</i>, 1996, 60(1):48-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8689811\">[PubMed 8689811]</a></p>\n<p>2. Vandel S, Bertschy G, Jounet JM et al, “Valpromide Increases the Plasma Concentrations of Amitriptyline and Nortriptyline in Depressive Patients,” <i>Ther Drug Monit</i>, 1988, 10(4):386-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3144066\">[PubMed 3144066]</a></p>\n<p>3. Fu C, Katzman M, Goldbloom DS, “Valproate/Nortriptyline Interaction,” <i>J Clin Psychopharmacol</i>, 1994, 14(3):205-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8027418\">[PubMed 8027418]</a></p>\n<p>4. Fehr C, Grunder G, Hiemke C, et al, “Increase in Serum Clomipramine Concentrations Caused by Valproate,” <i>J Clin Psychopharmacol</i>, 2000, 20(4):493-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10917416\">[PubMed 10917416]</a></p>\n<p>5. Prescribing information. Depakote (divalproex sodium). North Chicago, IL: Abbott Laboratories, April 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9522":"<p><b>Title</b> Valproate Products / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Protease Inhibitors may decrease the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to valproic acid and derivatives closely when starting/stopping or dose-adjusting protease inhibitor therapy. Protease inhibitors have been reported to reduce valproate plasma concentrations and clinical response. Altered doses of valproic acid and derivatives may be required.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> A study in HIV-infected patients reported a non-statistically-significant trend towards lower valproate concentrations in patients treated with valproic adie 250mg twice daily x 7 days and lopinavir/ritonavir (n=11) or efavirenz (n=10) vs. controls (n=11), though even the upper bounds of the 90% confidence interval for the average decrease were quite small.<sup>1</sup> Conversely, one case report describes a nearly 50% decrease in plasma valproate concentrations and loss of clinical effectiveness within 3 weeks of starting therapy with lopinavir/ritonavir, zidovudine, and lamivudine.<sup>2</sup> Similarly, the prescribing information of at least one protease inhibitor urges caution with concomitant valproic acid due to the possible risk of decreased valproate concentrations.<sup>3</sup> Another case report describes hepatoxicity (attributed to valproic acid) following the initiation of ritonavir, saquinavir, stavudine, and nevirapine in a patient started on valproic acid 5 weeks earlier.<sup>4</sup> The suspected mechanism behind the interactions reported in all of these instances is enhanced valproate metabolism caused by concurrent protease inhibitor therapy. Valproate undergoes complex metabolism, including glucuronidation, cytochrome P450-mediated metabolism (suspected to be via CYP2C9, CYP2B6, CYP2A6, CYP2E1, and possibly others), and multiple secondary conjugation reactions.<sup>1,5,6</sup> The protease inhibitors also have complex effects on drug metabolizing enzymes, generally considered potent inhibitors of CYP3A and other enzymes, but also inducers of glucuronidation and selected cytochromes P450 (e.g., CYP2B6, CYP2C9, CYP2C19).<sup>1,3,7</sup> Given these factors, protease inhibitor-mediated induction of valproate metabolism is certainly a plausible explanation for these clinical observations; however, the specifics of which enzyme(s) is/are responsible are uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sheehan NL, Brouillette MJ, Delisle MS, et al, “Possible Interaction between Lopinavir/Ritonavir and Valproic Acid Exacerbates Bipolar Disorder,” <i>Ann Pharmacother</i>, 2006, 40:147-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16368918\">[PubMed 16368918]</a></p>\n<p>2. DiCenzo R, Peterson D, Cruttenden K, et al, “Effects of Valproic Acid Coadministration on Plasma Efavirenz and Lopinavir Concentrations in Human Immunodeficiency Virus-Infected Adults,” <i>Antimicrob Agents Chemother</i>, 2004, 48:4328-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15504860\">[PubMed 15504860]</a></p>\n<p>3. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 10/2007.</p>\n<p>4. Cozza KL, Swanton EJ,Humphreys CW, “Hepatotoxicity with Combination of Valproic Acid, Ritonavir, and Nevirapine: A Case Report,” <i>Psychosomatics</i>, 2000, 41:452-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11015639\">[PubMed 11015639]</a></p>\n<p>5. Kiang TK, Ho PC, Anari MR, et al, “Contribution of CYP2C9, CYP2A6, and CYP2B6 to Valproic Acid Metabolism in Hepatic Microsomes from Individuals with the CYP2C9*1/*1 Genotype,” <i>Toxicol Sci</i>, 2006, 94:261-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16945988\">[PubMed 16945988]</a></p>\n<p>6. Neuman MG, Shear NH, Jacobson-Brown PM, et al, “CYP2E1-Mediated Modulation of Valproic Acid-Induced Hepatocytotoxicity,” <i>Clin Biochem</i>, 2001, 34:211-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11408019\">[PubMed 11408019]</a></p>\n<p>7. Yeh RF, Gaver VE, Patterson KB, et al, “Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 but Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers,” <i>J Acquir Immune Defic Syndr</i>, 2006, 42:52-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16639344\">[PubMed 16639344]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9523":"<p><b>Title</b> Valproate Products / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Though these combinations are commonly employed in antiseizure regimens, caution regarding potential adverse effects should be exercised. Monitor for increased serum concentrations/toxic effects of barbiturates if valproic acid or other valproate products are initiated/dose increased, or decreased serum concentrations/effects if valproic acid or other valproate products are discontinued/dose decreased. Dose adjustments may be necessary.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> The serum concentration and pharmacodynamic effects of phenobarbital have been reported to have increased significantly in a number of patients following the addition of valproate therapy.<sup>1,2,3,4,5,6</sup> Valproate appears to inhibit the metabolism of phenobarbital, possibly by inhibiting multiple metabolic pathways: CYP2C9 isoenzymes,<sup>7</sup> N-glucosidation,<sup>8</sup> and/or O-glucuronidation of p-hydroxyphenobarbital.<sup>8</sup> Other barbiturates will likely be affected in a similar manner.<br><br>Additionally, phenobarbital has been shown to be capable of significantly increasing the clearance of valproate.<sup>9</sup> The mechanism of this possible interaction is likely phenobarbital-mediated induction of valproate metabolism (via glucuronidation and CYP-mediated oxidation).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wilder BJ, Willmore LJ, Bruni J, et al, “Valproic Acid: Interaction With Other Anticonvulsant Drugs,” <i>Neurology</i>, 1978, 28:892. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=358012\">[PubMed 358012]</a></p>\n<p>2. Patel IH, Levy RH, and Cutler RE, “Phenobarbital-Valproic Acid Interaction,” <i>Clin Pharmacol Ther</i>, 1980, 27:515. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6766833\">[PubMed 6766833]</a></p>\n<p>3. Richens A and Ahmad S, “Controlled Trial of Sodium Valproate in Severe Epilepsy,” <i>Br Med J</i>, 1975, 3:255. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1104059\">[PubMed 1104059]</a></p>\n<p>4. Coulter DL, Wu H, and Allen RJ, “Valproic Acid Therapy in Childhood Epilepsy,” <i>JAMA</i>, 1980, 244:785. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6771426\">[PubMed 6771426]</a></p>\n<p>5. Kapetanovic IM, Kupferberg HJ, Porter RJ, et al, “Mechanism of Valproate-Phenobarbital Interaction in Epileptic Patients,” <i>Clin Pharmacol Ther</i>, 1981, 29:480. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6781810\">[PubMed 6781810]</a></p>\n<p>6. Fernandez de gatta MR, Alonso Gonzalez AC, Garcia Sanchez MJ, et al, “Effect of Sodium Valproate on Phenobarbital Serum Levels in Children and Adults,” <i>Ther Drug Monit</i>, 1986, 8:416-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3103264\">[PubMed 3103264]</a></p>\n<p>7. Hurst SI, Hargreaves JA, Howald WN, et al, “Enzymatic Mechanism for the Phenobarbital-Valproate Interaction,” <i>Epilepsia</i>, 1997, 38(Suppl 8):111.</p>\n<p>8. Bernus I, Dickinson RG, Hooper WD, et al, “Inhibition of Phenobarbitone N-Glucosidation by Valproate,” <i>Br J Clin Pharmacol</i>, 1994, 38:411-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7893581\">[PubMed 7893581]</a></p>\n<p>9. Prescribing information. Depakote ER (divalproex). North Chicago, IL: Abbott Laboratories, March 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9524":"<p><b>Title</b> CarBAMazepine / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may increase serum concentrations of the active metabolite(s) of CarBAMazepine. Parent carbamazepine concentrations may be increased, decreased, or unchanged. CarBAMazepine may decrease the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Closely monitor carbamazepine response and concentrations of carbamazepine and its active epoxide metabolite when used together with valproic acid or other valproate products, particularly after starting or stopping valproic acid. Carbamazepine dose adjustment may be needed. Also, monitor for decreased serum valproate concentrations/therapeutic effects if carbamazepine is initiated/dose increased, or increased serum concentrations or therapeutic effects if carbamazepine is discontinued/dose decreased.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Several clinical studies have described increases in concentrations of carbamazepine epoxide (CBZE), an active metabolite of carbamazepine (CBZ), as well as increases in the CBZE/CBZ ratio with concurrent use of valproic acid.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13</sup> These increases have generally been of relatively modest magnitude (approximately 30% to 80%) in most reports, but individual increases of more than 120% have been reported, and the increases in CBZE have been associated with clinical toxicity in some cases.<sup>2,12,13</sup> Additionally, this interaction appears to be age-dependent, with younger patients more sensitive to the interaction.<sup>1,4,14</sup> The impact of valproic acid on CBZ itself appears to be variable, with some reports of increased CBZ concentrations,<sup>2,4</sup> some of decreased CBZ concentrations,<sup>15,16</sup> and others reporting no change in CBZ concentrations.<sup>11,16</sup> The specific mechanism(s) for this apparent interaction is(are) uncertain, but valproic acid inhibition of CBZE metabolism via epoxide hydrolase and/or valproic acid inhibition of the conjugation of carbamazepine 10,11-transdiol have been suggested as likely mechanisms.<sup>1,3,17,18</sup><br><br>Data also demonstrate decreased serum valproate concentrations (by more than 60%) following the addition of carbamazepine.<sup>19,20</sup> Carbamazepine is a CYP2C9 and CYP2C19 isoenzyme inducer (and a possible inducer of glucuronidation), and thus may increase the metabolism of valproate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Minkova GD, Getova DP. Influence of carbamazepine-10,11-epoxide on the serum level of valproic acid in epileptic patients on combined treatment with carbamazepine and valproic acid. <i>Folia Med (Plovdiv)</i>. 2000;42(3):16-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11347330\">[PubMed 11347330]</a></p>\n<p>2. Potter JM, Donnelly A. Carbamazepine-10,11-epoxide in therapeutic drug monitoring. <i>Ther Drug Monit</i>. 1998;20(6):652-657. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9853982\">[PubMed 9853982]</a></p>\n<p>3. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. The mechanism of the carbamazepine-valproate interaction in humans. <i>Br J Clin Pharmacol</i>. 1997;44(1):21-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9241092\">[PubMed 9241092]</a></p>\n<p>4. Svinarov DA, Pippenger CE. Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase? <i>Ther Drug Monit</i>. 1995;17(3):217-220. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7624916\">[PubMed 7624916]</a></p>\n<p>5. McKee PJ, Blacklaw J, Butler E, Gillham RA, Brodie MJ. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. <i>Epilepsy Res</i>. 1992;11(3):193-198. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1396534\">[PubMed 1396534]</a></p>\n<p>6. Ramsay RE, McManus DQ, Guterman A, et al. Carbamazepine metabolism in humans: effect of concurrent anticonvulsant therapy. <i>Ther Drug Monit</i>. 1990;12(3):235-241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2112276\">[PubMed 2112276]</a></p>\n<p>7. Macphee GJ, Mitchell JR, Wiseman L, et al. Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man. <i>Br J Clin Pharmacol</i>. 1988;25(1):59-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3130892\">[PubMed 3130892]</a></p>\n<p>8. Elyas AA, Patsalos PN, Agbato OA, Brett EM, Lascelles PT. Factors influencing simultaneous concentrations of total and free carbamazepine and carbamazepine-10,11-epoxide in serum of children with epilepsy. <i>Ther Drug Monit</i>. 1986;8(3):288-292. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3750372\">[PubMed 3750372]</a></p>\n<p>9. Brodie MJ, Forrest G, Rapeport WG. Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants. <i>Br J Clin Pharmacol</i>. 1983;16(6):747-749. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6661364\">[PubMed 6661364]</a></p>\n<p>10. McKauge L, Tyrer JH, Eadie MJ. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. <i>Ther Drug Monit</i>. 1981;3(1):63-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7233491\">[PubMed 7233491]</a></p>\n<p>11. Pisani F, Fazio A, Oteri G, et al. Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients. <i>Epilepsia</i>. 1986;27(5):548-552. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3093212\">[PubMed 3093212]</a></p>\n<p>12. McKee RJ, Larkin JG, Brodie MJ. Acute psychosis with carbamazepine and sodium valproate. <i>Lancet</i>. 1989;1(8630):167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2563088\">[PubMed 2563088]</a></p>\n<p>13. Rambeck B, Salke-Treumann A, May T, Boenigk HE. Valproic acid-induced carbamazepine-10,11-epoxide toxicity in children and adolescents. <i>Eur Neurol</i>. 1990;30(2):79-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2111243\">[PubMed 2111243]</a></p>\n<p>14. Svinarov DA, Pippenger CE. Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication. <i>Ther Drug Monit</i>. 1996;18(6):660-665. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8946662\">[PubMed 8946662]</a></p>\n<p>15. Levy RH, Moreland TA, Morselli PL, Guyot M, Brachet-Liermain A, Loiseau P. Carbamazepine/valproic acid interaction in man and rhesus monkey. <i>Epilepsia</i>. 1984;25(3):338-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6426944\">[PubMed 6426944]</a></p>\n<p>16. Wilder BJ, Willmore LJ, Bruni J, Villarreal HJ. Valproic acid: interaction with other anticonvulsant drugs. <i>Neurology</i>. 1978;28(9, pt 1):892-896. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=358012\">[PubMed 358012]</a></p>\n<p>17. Robbins DK, Wedlund PJ, Kuhn R, Baumann RJ, Levy RH, Chang SL. Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine. <i>Br J Clin Pharmacol</i>. 1990;29(6):759-762. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2116161\">[PubMed 2116161]</a></p>\n<p>18. Pisani F, Caputo M, Fazio A, et al. Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. <i>Epilepsia</i>. 1990;31(3):339-342. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2111769\">[PubMed 2111769]</a></p>\n<p>19. Bowdle TA, Levy RH, Cutler RE. Effects of carbamazepine on valproic acid kinetics in normal subjects. <i>Clin Pharmacol Ther</i>. 1979;26(5):629-634. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=387328\">[PubMed 387328]</a></p>\n<p>20. May T, Rambeck B. Serum concentrations of valproic acid: influence of dose and comedication. <i>Ther Drug Monit</i>. 1985;7(4):387-390. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3936236\">[PubMed 3936236]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9525":"<p><b>Title</b> Valproate Products / ChlorproMAZINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> ChlorproMAZINE may increase the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor clinical response and valproate concentrations closely when valproic acid or other valproate products are used together with chlorpromazine, particularly when starting or stopping chlorpromazine.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> A study in patients with schizophrenia who were already taking valproate (200mg twice daily) found that addition of chlorpromazine (100-300mg/day) was associated with an average 22% increase in minimum valproate concentrations (n=25 samples from 6 patients).<sup>1</sup> No changes in valproate concentrations were observed in a separate group of patients (n=6) taking haloperidol.<sup>1</sup> The mechanism for this apparent interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ishizaki T, Chiba K, Saito M, et al, “The Effects of Neuroleptics (Haloperidol and Chlorpromazine) on the Pharmacokinetics of Valproic Acid in Schizophrenic Patients,” <i>J Clin Psychopharmacol</i>, 1984, 4(5):254-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6149238\">[PubMed 6149238]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9526":"<p><b>Title</b> Valproate Products / ClonazePAM</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> ClonazePAM may diminish the therapeutic effect of Valproate Products. Valproate Products may decrease the serum concentration of ClonazePAM. ClonazePAM may increase the serum concentration of Valproate Products. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Valproic acid prescribing information cautions that concomitant use with clonazepam may induce absence status in patients with a history of absence type seizures.<sup>1</sup> However, data supporting this possible interaction are lacking. Rather, the combination of valproate and clonazepam has been shown to be an effective combination for even intractable cases of absence seizures in smaller observational studies.<sup>2,3</sup><br><br>The mechanism for any possible valproate -- clonazepam interaction is unclear. One pharmacokinetic study employing mixed effect modeling in the analysis of 576 drug concentrations from 317 patients estimated that valproate increased clonazepam clearance by 14% and that clonazepam decreased valproate clearance by 18%.<sup>4</sup> Conversely, a small study of 4 patients with seizures uncontrolled by valproate found that the addition of clonazepam had no effect on valproate concentrations.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Depakene (valproic acid). Corona, CA: Watson Pharma, Inc, April 2009.</p>\n<p>2. Mireles R, Leppik IE, “Valproate and Clonazepam Comedication in Patients with Intractable Epilepsy,” <i>Epilepsia</i>, 1985, 26:122-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3921350\">[PubMed 3921350]</a> </p>\n<p>3. Berkovic SF, Bladin PF, “Absence Status in Adults,” <i>Clin Exp Neurol</i>, 1983, 19:198-207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6439444\">[PubMed 6439444]</a> </p>\n<p>4. Yukawa E, Nonaka T, Yukawa M, et al, “Pharmacoepidemiologic Investigation of a Clonazepam-Valproic Acid Interaction by Mixed Effect Modeling Using Routine Clinical Pharmacokinetic Data in Japanese Patients,” <i>J Clin Pharm Ther</i>, 2003, 28:497-504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14651674\">[PubMed 14651674]</a> </p>\n<p>5. Wang L, Wang XD, “Pharmacokinetic and Pharmacodynamic Effects of Clonazepam in Children with Epilepsy Treated with Valproate: A Preliminary Study,” <i>Ther Drug Monit</i>, 2002, 24:532-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12142639\">[PubMed 12142639]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9527":"<p><b>Title</b> Valproate Products / Cosyntropin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction applies to the cosynotropin intramuscular depot formulation.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cosyntropin may enhance the hepatotoxic effect of Valproate Products. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of Synacthen Depot (dosage form available in Canada) with valproic acid or other valproate products.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Synacthen Depot (cosyntropin) Canadian product monograph recommends avoiding concomitant use with valproate.<sup>1</sup> Severe jaundice has been observed with concomitant use in pediatric patients. The depot is approved for diagnostic and therapeutic use in Canada. The manufacturer labeling does not indicate whether or not the adverse events were associated only with prolonged (therapeutic) use.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Synacthen Depot (cosyntropin). Dorval, Quebec: Novartis Pharmaceuticals Canada Inc., May 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9528":"<p><b>Title</b> DiazePAM / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Valproate Products may increase the serum concentration of DiazePAM. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Serum concentrations of unbound diazepam (administered IV) were increased approximately twofold in 6 normal subjects when coadminsitered with sodium valproate (1500 mg daily).<sup>1</sup> The mechanism of this pharmacokinetic alteration is unclear. No evidence of clinical concern is available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dhillon S and Richens A, “Valproic Acid and Diazepam Interaction In Vivo,” <i>Br J Clin Pharmacol</i>, 1982, 13(4):553-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6802161\">[PubMed 6802161]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9529":"<p><b>Title</b> Ethosuximide / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ethosuximide may decrease the serum concentration of Valproate Products. Valproate Products may increase the serum concentration of Ethosuximide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor both ethosuximide and valproate concentrations (and clinical response) closely when using these agents in combination, and particularly when starting/stopping or adjusting the dose of one or both drugs.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> According to one case series, the addition of valproic acid to ethosuximide therapy in with poorly controlled seizures was associated with increased ethosuximide concentrations (by an average of 53%) in 4 of the 5 patients.<sup>1</sup> A small pharmacokinetic study in 6 healthy volunteers supported this observation, reporting a 23% increase in ethosuximide half-life and a 15% reduction in ethosuximide clearance following 9 days of valproic acid (800-1600mg per day).<sup>2</sup> Of note, the interaction appeared highly variable in this study, with 2 of the 6 volunteers showing no evidence of an interaction. Conversely, another study in 6 healthy volunteers found no significant changes in ethosuximide pharmacokinetics following the addition of valproic acid.<sup>3</sup> Whether the absence of an interaction in this study further reflects the variability in response to the combination or simply raises questions about the existence and significance of the interaction is unclear. The specific mechanism of this possible interaction is unclear, but valproate appears to inhibit the metabolism of ethosuximide. Valproate has been shown to interfere with the metabolism and/or protein binding of numerous other drugs.<br><br>Additionally, one uncontrolled study has reported evidence that ethosuximide may decrease valproate concentrations.<sup>4</sup> Patients receiving both ethosuximide and valproic acid had lower valproate concentrations (27.5% lower) than those receiving valproic acid alone. Similarly, following discontinuation of ethosuximide, valproate concentrations increased by an average of almost 37%. The mechanism of this apparent interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mattson RH,Cramer JA, “Valproic Acid and Ethosuximide Interaction,” <i>Ann Neurol</i>, 1980, 7:583-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6776874\">[PubMed 6776874]</a></p>\n<p>2. Pisani F, Narbone MC, Trunfio C, et al, “Valproic Acid-Ethosuximide Interaction: A Pharmacokinetic Study,” <i>Epilepsia</i>, 1984, 25:229-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6423377\">[PubMed 6423377]</a></p>\n<p>3. Bauer LA, Harris C, Wilensky AJ, et al, “Ethosuximide Kinetics: Possible Interaction with Valproic Acid,” <i>Clin Pharmacol Ther</i>, 1982, 31:741-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6804151\">[PubMed 6804151]</a></p>\n<p>4. Salke-Kellermann RA, May T,Boenigk HE, “Influence of Ethosuximide on Valproic Acid Serum Concentrations,” <i>Epilepsy Res</i>, 1997, 26:345-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9095396\">[PubMed 9095396]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9530":"<p><b>Title</b> Valproate Products / Felbamate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Felbamate may increase the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> In patients receiving valproic acid or other valproate products, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily while reducing dose of the valproate product by 20%. Monitor for increased concentrations/toxic effects of valproate and decreased concentrations/therapeutic effects of felbamate.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Prescribing information for felbamate cites data in four patients in whom felbamate coadministration increased steady-state minimum concentrations of valproate by 23% and 52%, at doses of 1,200 mg and 2,400 mg felbamate daily, respectively.<sup>1</sup> Protein binding of valproate was not appreciably altered. In a study of 10 epileptic patients, the mean AUC of valproate was increased by 28% and 54% following the addition of daily felbamate at dosages of 1200 mg and 2400 mg, respectively.<sup>2</sup> Other clinical studies have confirmed increases in valproate concentrations, in patients as well as healthy volunteers, with felbamate coadministration.<sup>3,4</sup> Toxicities related to this interaction have been reported, and include nausea, headache, dizziness, ataxia, drowsiness, changes in cognition, and decreased platelets.<sup>2,4,5,6,7</sup> <br><br>In a population pharmacokinetic study, valproate coadministration was associated with an estimated 21% decrease in felbamate clearance in children (based on clinical drug concentration monitoring), but data confirming this effect are lacking.<sup>8</sup><br><br>The likely primary mechanism of this interaction is felbamate inhibition of CYP2C19 mediated valproate metabolism. The mechanism by which valproate may decrease felbamate concentrations is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Felbatol (felbamate). Somerset, NJ: Meda Pharmaceuticals Inc., 6/08.</p>\n<p>2. Wagner ML, Graves NM, Leppik IE, et al, “The Effect of Felbamate on Valproic Acid Disposition,” <i>Clin Pharmacol Ther</i>, 1994, 56:494-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7955813\">[PubMed 7955813]</a></p>\n<p>3. Siegel H, Kelley K, Stertz B, et al, “The Efficacy of Felbamate as Add-On Therapy to Valproic Acid in the Lennox-Gastaut Syndrome,” <i>Epilepsy Res</i>, 1999, 34(2-3):91-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10210023\">[PubMed 10210023]</a></p>\n<p>4. Hooper WD, Franklin ME, Glue P, et al, “Effect of Felbamate on Valproic Acid Disposition in Healthy Volunteers: Inhibition of Beta-Oxidation,” <i>Epilepsia</i>, 1996, 37(1):91-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8603632\">[PubMed 8603632]</a></p>\n<p>5. Ward DL, Wagner ML, Perhach JL, et al, “Felbamate Steady-State Pharmacokinetics During Coadministration of Valproate,” <i>Epilepsia</i>, 1991, 33(Suppl 3):8.</p>\n<p>6. Liu H and Delgado MR, “Significant Drug Interaction Between Valproate and Felbamate in Epileptic Children,” <i>Epilepsia</i>, 1995, 36(Suppl 3):S160.</p>\n<p>7. Ney GC, Schaul N, Loughlin J, et al, “Thrombocytopenia in Association With Adjunctive Felbamate Use,” <i>Neurology</i>, 1994, 44(5):980-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8190314\">[PubMed 8190314]</a></p>\n<p>8. Kelley MT, Walson PD, Cox S, et al, “Population Pharmacokinetics of Felbamate in Children,” <i>Ther Drug Monit</i>, 1997, 19(1):29-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9029743\">[PubMed 9029743]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9531":"<p><b>Title</b> Fosphenytoin-Phenytoin / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may decrease the protein binding of Fosphenytoin-Phenytoin. This appears to lead to an initial increase in the percentage of unbound (free) phenytoin and to a decrease in total phenytoin concentrations. Whether concentrations of free phenytoin are increased is unclear. With long-term concurrent use, total phenytoin concentrations may increase. Fosphenytoin-Phenytoin may decrease the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of phenytoin toxicity in the days and weeks following addition (or dose increase) of any concurrent valproate product. The percentage of free (unbound) phenytoin may increase, but the total phenytoin concentration may decrease. With long-term concurrent use, total phenytoin concentrations may return to pre-valproate levels or to levels higher than those observed prior to valproate. Consider monitoring free phenytoin concentrations in patients receiving this combination when available and appropriate. If monitoring total phenytoin concentrations, be aware that the percentage of free phenytoin may be higher with concurrent use of valproate. Additionally, monitor for decreased serum concentrations of valproate, and the potential for hepatotoxicity due to the increased presence of a hepatotoxic metabolite if phenytoin is initiated/dose increased.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Though often coadministered in advantageous, uneventful fashion, the combination of phenytoin and valproic acid carries some reported risks which should be understood and managed. Several reports describe evidence of phenytoin toxicity, with or without an increase in the percentage of unbound (free) phenytoin and a decrease in total (free and protein bound) phenytoin soon after initiation of concurrent valproate therapy.<sup>1,2,3</sup> Several other case series and studies similarly concluded that initiation of valproate was associated with an increase in the free fraction of phenytoin and/or an initial decrease in total phenytoin concentration.<sup>4,5,6,7,8,9,10,11,12</sup> Two of these reports noted no significant change in the concentration of free phenytoin,<sup>4,5</sup> suggesting that the free phenytoin may be cleared relatively quickly, which could also explain the reported decrease in total phenytoin concentrations that were observed together with the increase in percentage unbound. Also, with continued combination therapy (ie, for a period of several weeks to months) an eventual return to or beyond baseline concentrations of total phenytoin has also been reported,<sup>6,7</sup> which may suggest that valproate is capable of inhibiting the metabolism of phenytoin to some degree. The mechanisms of this likely two-fold interaction appear to be 1) initial displacement of phenytoin from its protein binding sites by valproate, and 2) eventual inhibition of phenytoin metabolism via an unclear mechanism.<br><br>There is also evidence that phenytoin administration can lead to reduced valproate serum concentrations.<sup>13</sup> The mechanism is unclear but may be due to phenytoin induction of valproate metabolism. It has also been suggested that such increased metabolism might possibly increase the serum concentration of hepatotoxic valproate metabolites.<sup>14</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chan K, Beran RG. Value of therapeutic drug level monitoring and unbound (free) levels. <i>Seizure</i>. 2008;17(6):572-575. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18262440\">[PubMed 18262440]</a></p>\n<p>2. Carvalho IV, Carnevale RC, Visacri MB, et al. Drug interaction between phenytoin and valproic acid in a child with refractory epilepsy: a case report. <i>J Pharm Pract</i>. 2014;27(2):214-216. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24381240\">[PubMed 24381240]</a></p>\n<p>3. Tollefson GD. Delirium induced by the competitive interaction between phenytoin and dipropylacetate. <i>J Clin Psychopharmacol</i>. 1981;1(3):154-158. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6795246\">[PubMed 6795246]</a></p>\n<p>4. Mattson RH, Cramer JA, Williamson PD, Novelly RA. Valproic acid in epilepsy: clinical and pharmacological effects. <i>Ann Neurol</i>. 1978;3(1):20-25. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=350128\">[PubMed 350128]</a></p>\n<p>5. Tsanaclis LM, Allen J, Perucca E, Routledge PA, Richens A. Effect of valproate on free plasma phenytoin concentrations. <i>Br J Clin Pharmacol</i>. 1984;18(1):17-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6430316\">[PubMed 6430316]</a></p>\n<p>6. Bruni J, Gallo JM, Lee CS, Perchalski RJ, Wilder BJ. Interactions of valproic acid with phenytoin. <i>Neurology</i>. 1980;30(11):1233-1236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6775245\">[PubMed 6775245]</a></p>\n<p>7. Bruni J, Wilder BJ, Willmore LJ, Barbour B. Valproic acid and plasma levels of phenytoin. <i>Neurology</i>. 1979;29(6):904-905. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=377134\">[PubMed 377134]</a></p>\n<p>8. ter Heine R, van Maarseveen EM, van der Westerlaken MM, et al. The quantitative effect of serum albumin, serum urea, and valproic acid on unbound phenytoin concentrations in children. <i>J Child Neurol</i>. 2014;29(6):803-810. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23670246\">[PubMed 23670246]</a></p>\n<p>9. Joerger M, Huitema AD, Boogerd W, van der Sande JJ, Schellens JH, Beijnen JH. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. <i>Basic Clin Pharmacol Toxicol</i>. 2006;99(2):133-140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16918714\">[PubMed 16918714]</a></p>\n<p>10. Mamiya K, Yukawa E, Matsumoto T, Aita C, Goto S. Synergistic effect of valproate coadministration and hypoalbuminemia on the serum-free phenytoin concentration in patients with severe motor and intellectual disabilities. <i>Clin Neuropharmacol</i>. 2002;25(4):230-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12151911\">[PubMed 12151911]</a></p>\n<p>11. Friel PN, Leal KW, Wilensky AJ. Valproic acid-phenytoin interaction. <i>Ther Drug Monit</i>. 1979;1(2):243-248. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=122160\">[PubMed 122160]</a></p>\n<p>12. Perucca E, Hebdige S, Frigo GM, Gatti G, Lecchini S, Crema A. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. <i>Clin Pharmacol Ther</i>. 1980;28(6):779-789. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6777108\">[PubMed 6777108]</a></p>\n<p>13. May T, Rambeck B. Serum concentrations of valproic acid: influence of dose and comedication. <i>Ther Drug Monit</i>. 1985;7(4):387-390. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3936236\">[PubMed 3936236]</a></p>\n<p>14. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. <i>Neurology</i>. 1987;37(3):379-385. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3102998\">[PubMed 3102998]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9532":"<p><b>Title</b> Valproate Products / GuanFACINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> GuanFACINE may increase the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to valproic acid and other valproate products closely when starting or stopping concurrent guanfacine. Valproate concentrations (and effects) would be expected to increase when starting (or increasing dose of) guanfacine, and valproate concentrations (and effects) would be expected to decrease when stopping (or decreasing) guanfacine.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> A case report describes similar interactions between guanfacine and valproic acid in 2 pediatric (8 yrs old and 9 yrs old) patients. In one patient, discontinuation of guanfacine was associated with a 41% decrease in valproate concentrations, and in the other patient, valproate concentrations increased following the addition of guanfacine.<sup>1</sup><br><br>The specific mechanism of this apparent interaction is uncertain, though guanfacine prescribing information proposes that the interaction may be the result of competition between valproate and a particular guanfacine metabolite (3-hydroxy guanfacine) for glucuronidation enzymes.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ambrosini PJ, Sheikh RM, “Increased Plasma Valproate Concentrations when Coadministered with Guanfacine,” <i>J Child Adolesc Psychopharmacol</i>, 1998, 8(2):143-7. [PMID: 9730080]</p>\n<p>2. Prescribing information. Intuniv (guanfacine). Wayne, PA: Shire US Inc., August 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9534":"<p><b>Title</b> Valproate Products / Isoniazid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isoniazid may increase the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased serum valproate concentrations/toxic effects if isoniazid is initiated/dose increased, or decreased effects if isoniazid is discontinued/dose decreased.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> The serum concentrations of valproate, and associated toxicities, increased in a 5-year-old patient receiving valproic acid following the addition of isoniazid therapy.<sup>1</sup> The patient was restabilized on a dose of valproic acid that was 62% lower than her pre-isoniazid dose. Subsequent discontinuation of isoniazid was met with a substantial decrease in valproate serum concentrations, and increased seizure activity. The mechanism of this interaction is unknown. It appears that isoniazid might decrease the metabolism of valproate via CYP enzyme inhibition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Jonville AP, Gauchez AS, Autret E, et al, “Interaction Between Isoniazid and Valproate: A Case of Valproate Overdosage,” <i>Eur J Clin Pharmacol</i>, 1991, 40:197-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2065702\">[PubMed 2065702]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9535":"<p><b>Title</b> LamoTRIgine / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Valproate Products may enhance the adverse/toxic effect of LamoTRIgine. Valproate Products may increase the serum concentration of LamoTRIgine. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Decrease the dose of lamotrigine by 50% when used concomitant with valproic acid or other valproate products. Monitor for increased serum concentrations/toxic effects (specifically toxic epidermal necrolysis) of lamotrigine if valproate products are initiated/dose increased, or decreased effects if valproate products are discontinued/dose decreased.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Serum lamotrigine concentrations in patients receiving concomitant valproic acid were approximately double the values of those in patients not receiving valproic acid (n=302).<sup>1</sup> The dosage of the lamotrigine in the valproic acid group was approximately 1/2 of the dosage of those not receiving valproic acid. The AUC of lamotrigine was decreased by approximately 30% in 6 normal subjects when receiving concomitant valproate (200 mg every 8 hours).<sup>2</sup> In addition to these pharmacokinetic changes, a case report describes the development of toxic epidermal necrolysis in a valproic acid-treated patient within approximately one month of initiating lamotrigine therapy.<sup>3</sup> The mechanism(s) of these interactions is unclear. The agents may compete for sites of metabolism (e.g. glucuronidation), or valproate may inhibit p-glycoprotein, and thus decrease lamotrigine presentation to metabolic enzymes. Whether valproate increases the risk of lamotrigine-induced toxic epidermal necrolysis is unknown, but the seriousness of this effect deserves attention.</p> \n<p><b>Footnotes</b> </p>\n<p>1. May TW, Rambeck B, and Jurgens U, “Serum Concentrations of Lamotrigine in Epileptic Patients: The Influence of Dose and Comedication,” <i>Ther Drug Monit</i>, 1996, 18:523-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8885114\">[PubMed 8885114]</a></p>\n<p>2. Yuen AW, Land G, Weatherley BC, et al, “Sodium Valproate Acutely Inhibits Lamotrigine Metabolism,” <i>Br J Clin Pharmacol</i>, 1992, 33:511-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1524964\">[PubMed 1524964]</a></p>\n<p>3. Page RL II, O'Neil MG, Yarbrough DR III, et al, “Fatal Toxic Epidermal Necrolysis Related to Lamotrigine Administration,” <i>Pharmacotherapy</i>, 1998, 18:392. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9545161\">[PubMed 9545161]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9536":"<p><b>Title</b> LevETIRAcetam / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Valproate Products do not appear to affect serum concentration of LevETIRAcetam. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> The AUC of levetiracetam (1500 mg single dose) was unaltered in 16 normal subjects when administered following an 8-day course of valproic acid (500 mg twice daily).<sup>1</sup> The single dose of levetiracetam did not affect the steady state pharmacokinetics of valproate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Coupez R, Nicolas JM, and Browne TR, “Levetiracetam, a New Antiepileptic Agent: Lack of <i>in vitro</i> and <i>in vivo</i> Pharmacokinetic Interaction With Valproic Acid,” <i>Epilepsia</i>, 2003, 44(2):171-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12558570\">[PubMed 12558570]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9537":"<p><b>Title</b> LORazepam / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Valproate Products may increase the serum concentration of LORazepam. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased effects of lorazepam, particularly CNS depression, if lorazepam is coadministered with valproic acid or other valproate products. Product labeling recommends a 50% dose reduction of lorazepam when concurrent therapy is employed.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Product labeling recommends a 50% dose reduction of lorazepam when concurrent valproate therapy is employed.<sup>1</sup> Prospective studies in healthy volunteers evaluated the effects of valproic acid on lorazepam metabolism. In a nonrandomized, open-label, controlled investigation, 8 subjects received a bolus dose of lorazepam (2 mg IV) with divalproex (250 mg twice daily, 3 days prior to, and 4 days after bolus administration).<sup>2</sup> After a wash-out period, subjects were administered the same lorazepam bolus in the absence of valproate. In the presence of valproate, formation of the lorazepam glucuronide decreased approximately 58% in 6 of the 8 subjects, accompanied by a 40% reduction in plasma lorazepam clearance (both parameters p&lt;0.05) as compared to lorazepam alone. In a subsequent prospective, double-blinded study, 16 volunteers received a 12-day regimen of divalproex sodium (500mg every 12 hours) with lorazepam (1 mg every 12 hours) on days 6-9, and morning of the 10th.<sup>3</sup> Participants were then crossed-over to receive lorazepam in the same manner during a 12-day placebo regimen. Again, formation of the lorazepam glucuronide was reduced by just over 30%, with a 20% increase in serum lorazepam (parent drug) levels (p&lt;0.05). <br><br>Decreased clearance of lorazepam may lead to serious consequences in select patients, as suggested by a case report documenting development of a comatose state in a patient receiving lorazepam in the setting of mutiple anticonvulsant medications, including valproate.<sup>4</sup> The patient was a 36 year-old woman on stable valproate (1000 mg/day), phenytoin (300 mg/day) and carbamazepine (400 mg/day) therapy for intractable seizures. After receiving a total of 6 mg lorazepam intravenously over the course of 24 hours, the patient was found to be unconscious and unresponsive, despite normal serum valproate levels. The authors attributed the event to valproate-induced augmentation of lorazepam effects.<br><br>The mechanism of this interaction is likely due to a valproate-mediated reduction in glucuronide metabolism of lorazepam.<sup>5</sup> Clearance of lorazepam is thought to be governed in large part by a glucuronidation reaction mediated by UDP glucuronosyltransferase (UGT) enzymes, as evidenced by significantly reduced clearance in individuals with a reduced function UGT genotype.<sup>6</sup> Previous observations have shown that valproate is capable of inhibiting the glucuronide conjugation metabolism of carbamazepine.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ativan (lorazepam). Philadelphia, PA: Wyeth Pharmaceuticals, 2007.</p>\n<p>2. Anderson GD, Gidal BE, Kantor ED, et al, “Lorazepam-Valproate Interaction: Studies in Normal Subjects and Isolated Perfused Rat Liver,” <i>Epilepsia</i>, 1994, 35(1):221-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8112251\">[PubMed 8112251]</a> </p>\n<p>3. Samara EE, Granneman RG, Witt GF, et al, “Effect of Valproate on the Pharmacokinetics and Pharmacodynamics of Lorazepam,” <i>J Clin Pharmacol</i>, 1997, 37(5):442-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9156377\">[PubMed 9156377]</a></p>\n<p>4. Lee SA, Lee JK, Heo K, “Coma Probably Induced by Lorazepam-Valproate Interaction,” <i>Seizure</i>, 2002, 11(2):124-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11945099\">[PubMed 11945099]</a></p>\n<p>5. Kiang TKL, Ensom MHH, Chang TKH, “UDP-Glucuronosyltransferases and Clinical Drug-Drug Interactions,” <i>Pharmacol Ther</i>, 2005, 106:97-132. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15781124\">[PubMed 15781124]</a></p>\n<p>6. Chung JY, Cho JY, Yu KS, et al, “Effect of the UGT2B15 Genotype on the Pharmacokinetics, Pharmacodynamics, and Drud Interactions of Intravenous Lorazepam in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 2005, 77(6):486-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15961980\">[PubMed 15961980]</a></p>\n<p>7. Bernus I, Dickinson RG, Hooper WD, et al, “The Mechanism of the Carbamazepine-Valproate Interaction in Humans,” <i>Br J Clin Pharmacol</i>, 1997, 44:21-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9241092\">[PubMed 9241092]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9538":"<p><b>Title</b> Valproate Products / Methylfolate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methylfolate may decrease the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum valproate concentrations and effectiveness if L-methylfolate is initiated/dose increased. Similarly, monitor for increases in valproate concentrations (and possible toxicity) if L-methylfolate is discontinued/dose decreased.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> L-methylfolate (primary biologically active isomer of folate) prescribing information cautions that high doses of folate may reduce serum levels of anticonvulsants (including valproic acid) and thus increase the seizure frequency in susceptible patients.<sup>1</sup> The exact mechanism by which folic acid may interact with valproic acid is uncertain, but it has been postulated that folates enhance a metabolic pathway of valproate that is common to many antiepileptic agents (parahydroxylation).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Deplin (L-methylfolate). Covington, LA: PAMLAB, L.L.C., 2006.</p>\n<p>2. Viukari NMA, “Folic Acid and Anticonvulsants,” <i>Lancet</i>, 1968, 1(7539):980. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4171606\">[PubMed 4171606]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9539":"<p><b>Title</b> Minoxidil (Systemic) / Valproate Products</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling warns of increased minoxidil effects with this combination, recommending avoidance or minoxidil dose reduction to avoid hypotension. US labeling does not mention this possible interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may increase the serum concentration of Minoxidil (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased minoxidil effects (eg, hypotension) if combined with valproic acid. Canadian product labeling recommends avoiding this combination or reducing the minoxidil dose. US prescribing information does not warn of this potential interaction.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Canadian labeling for minoxidil warns that the combination of minoxidil and valproic acid may result in increased minoxidil concentrations and increased effects.<sup>1</sup> Avoidance of this combination or a minoxidil dose reduction accompanied with careful monitoring is recommended.<sup>1</sup> US product labeling for minoxidil does not warn of this potential interaction.<sup>2</sup><br><br>The mechanism of this proposed interaction is that valproic acid is a weak inhibitor of various UDP-glucuronosyltransferases (UGTs) and UGTs are responsible for the majority of minoxidil metabolism.<sup>1,2,3</sup> The specific UGT isoforms that valproic acid may inhibit, as well as those responsible for minoxidil metabolism, are unknown.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Loniten</i> (minoxidil) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; November 2013.</p>\n<p>2. <i>Loniten</i> (minoxidil) [prescribing information]. New York, NY: Pfizer Inc; January 2015.</p>\n<p>3. <i>Depakene</i> (valproic acid) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9540":"<p><b>Title</b> NiMODipine / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Valproate Products may increase the serum concentration of NiMODipine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> The AUC of nimodopine (60 mg single dose) was increased approximately 50% in patients receiving valproate.<sup>1</sup> The mechanism of this pharmacokinetic effect is unclear. The clinical implications appear minimal.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tartara A, Galimberti CA, Manni R, et al, “Differential Effects of Valproic Acid and Enzyme-Inducing Anticonvulsants on Nimodipine Pharmacokinetics in Epileptic Patients,” <i>Br J Clin Pharmacol</i>, 1991, 32(3):335-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1777370\">[PubMed 1777370]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9541":"<p><b>Title</b> OLANZapine / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may decrease the serum concentration of OLANZapine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreases in olanzapine concentrations and therapeutic effect when adding or increasing valproic acid. Similarly, if stopping valproic acid in a patient who has been maintained on this combination, monitor the patient for increased olanzapine concentrations and effects.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> An analysis of a cohort of 92 patients who had been receiving olanzapine together with valproic acid reported an average 32% reduction in the olanzapine concentration/dose ratio compared to controls who were not receiving any concurrent antiepileptic (n=205 patients), after an average of 7 days of valproic acid initiation at an average of 20 mg/day.<sup>1</sup> Two previous articles showed similar results, with a case series reporting a 32% to 79% percent reduction of plasma olanzapine concentrations in 4 patients following the addition of valproic acid,<sup>2</sup> and a 21-patient open-label drug interaction study reporting an average 18% reduction in serum olanzapine concentrations after valproic acid (600-2000 mg/day) was added to patients previously stabilized on olanzapine.<sup>3</sup><br><br>The mechanism(s) for this interaction is(are) uncertain, but induction of p-glycoprotein by valproic acid and/or protein (albumin) binding displacement leading to lower measured serum olanzapine concentrations have been proposed as possible mechanisms.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Haslemo T, Olsen K, Lunde H, et al, “Valproic Acid Significantly Lowers Serum Concentrations of Olanzapine-An Interaction Effect Comparable with Smoking,” <i>Ther Drug Monit</i>, 2012, 34(5):512-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22972535\">[PubMed 22972535]</a></p>\n<p>2. Bergemann N, Kress KR, Abu-Tair F, et al, “Valproate Lowers Plasma Concentration of Olanzapine,” <i>J Clin Psychopharmacol</i>, 2006, 26(4):432-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16855466\">[PubMed 16855466]</a></p>\n<p>3. Spina E, D’Arrigo C, Santoro V, et al, “Effect of Valproate on Olanzapine Plasma Concentrations in Patients with Bipolar or Schizoaffective Disorder,” <i>Ther Drug Monit</i>, 2009, 31(6):758-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19865002\">[PubMed 19865002]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9542":"<p><b>Title</b> OXcarbazepine / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may decrease the serum concentration of OXcarbazepine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/effects of oxcarbazepine if valproic acid or other valproate products are initiated/dose increased, and increased concentrations/toxicity if these products are discontinued/dose decreased.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Serum concentrations of oxcarbazepine (600-1800 mg/day) were decreased an average of 18% in normal subjects when coadministered with valproic acid (400-2800 mg/day).<sup>1</sup> The change in oxcarbazepine was probably due to valproate-enhanced metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Trileptal (oxcarbazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9543":"<p><b>Title</b> Paliperidone / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may increase the serum concentration of Paliperidone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased paliperidone levels/effects with concomitant administration of valproic acid or other valproate products. Paliperidone dosage reduction may be necessary. Monitor for decreased paliperidone levels/effects with dose decrease/discontinuation of valproic acid or other valproate products.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Conflicting data exist regarding the potential for a drug-drug interaction between valproic acid and derivatives with paliperidone (active metabolite of risperidone). According to paliperidone prescribing information (PI), coadministration of paliperidone (12 mg as single dose) and divalproex sodium extended release (ER) tabs (1000 mg/daily), increased both paliperidone AUC and maximum serum concentration (C<sub>max</sub>) by approximately 50%.<sup>1</sup> <br><br>Conversely, serum levels of risperidone and paliperidone, were not significantly altered in two other studies of patients (n=10) receiving concomitant risperidone (4-8 mg/day) and sodium valproate (600-1500 mg/day) x 4 weeks,<sup>2</sup> or in patients (n=12) receiving risperidone (2-6 mg/day) and valproic acid (400-800 mg/day) x 4 weeks.<sup>3</sup><br><br>The underlying mechanism of any possible interaction is unclear. Paliperidone is metabolized to a limited extent by CYP2D6 and CYP3A4; however, valproate only weakly inhibits both of these enzymes, and as a result, only a small change, if any, in paliperidone serum concentrations would seem likely. Of note, in vitro studies demonstrate paliperidone to be a substrate of the P-glycoprotein (P-gp) transporter,<sup>1</sup> and valproate has been identified by some as a possible P-gp inhibitor.<sup>4</sup> What role (if any) that P-gp inhibition may play in this proposed interaction is not known.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invega (paliperidone). Titusville, NJ: Ortho-Mcneil-Janssen Pharmaceuticals, Inc., July 2009.</p>\n<p>2. Spina E, Avenoso A, Facciola G, et al, “Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone: Effect of Comedication With Carbamazepine or Valproate,” <i>Ther Drug Monit</i>, 22(4):481-85. [PMID 10942191]</p>\n<p>3. Yoshimura R, Shinkai K, Ueda N, et al, “Valproic Acid Improves Psychotic Agitation without Influencing Plasma Risperidone Levels in Schizophrenic Patients,” <i>Pharmacopsychiatry</i>, 2007, 40:9-13. [PMID 17327954]</p>\n<p>4. Weiss J, Kerpen CJ, Lindenmaier H, et al, “Interaction of Antiepileptic Drugs with Human P-Glycoprotein in Vitro,” <i>J Pharmacol Exp Ther</i>, 2003, 307(1):262-67. [PMID 12954800]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9544":"<p><b>Title</b> Primidone / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may decrease the metabolism of Primidone. More specifically, the metabolism of phenobarbital, primidone's primary active metabolite, may be decreased. Primidone may increase the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Though this is a commonly employed antiseizure regimen, caution regarding potential adverse effects should be exercised. Monitor for increased serum concentrations/toxic effects of phenobarbital (the active metabolite of primidone) if valproic acid or other valproate products are initiated/dose increased, or decreased serum concentrations/effects if these products are discontinued/dose decreased. In addition, monitor valproate concentrations closely when adjusting primidone therapy. Dose adjustments may be necessary.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Primidone is metabolized to phenobarbital, <i>in vivo</i>. The serum concentration and pharmacodynamic effects of phenobarbital have been reported to have increased significantly in a number of patients following the addition of valproate therapy.<sup>1,2,3,4,5,6</sup> Valproate appears to inhibit the metabolism of phenobarbital, possibly by inhibiting multiple metabolic pathways: CYP2C9 isoenzymes,<sup>7</sup> N-glucosidation,<sup>8</sup> and/or O-glucuronidation of p-hydroxyphenobarbital.<sup>8</sup> Valproate would thus be anticipated to increase the phenobarbital concentrations in patients receiving primidone.<br><br>Additionally, phenobarbital has been shown to be capable of significantly increasing the clearance of valproate.<sup>9</sup> The mechanism of this possible interaction is likely phenobarbital-mediated induction of valproate metabolism (via glucuronidation and CYP-mediated oxidation).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wilder BJ, Willmore LJ, Bruni J, et al, “Valproic Acid: Interaction With Other Anticonvulsant Drugs,” <i>Neurology</i>, 1978, 28:892. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=358012\">[PubMed 358012]</a></p>\n<p>2. Patel IH, Levy RH, and Cutler RE, “Phenobarbital-Valproic Acid Interaction,” <i>Clin Pharmacol Ther</i>, 1980, 27:515. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6766833\">[PubMed 6766833]</a></p>\n<p>3. Richens A and Ahmad S, “Controlled Trial of Sodium Valproate in Severe Epilepsy,” <i>Br Med J</i>, 1975, 3:255. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1104059\">[PubMed 1104059]</a></p>\n<p>4. Coulter DL, Wu H, and Allen RJ, “Valproic Acid Therapy in Childhood Epilepsy,” <i>JAMA</i>, 1980, 244:785. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6771426\">[PubMed 6771426]</a></p>\n<p>5. Kapetanovic IM, Kupferberg HJ, Porter RJ, et al, “Mechanism of Valproate-Phenobarbital Interaction in Epileptic Patients,” <i>Clin Pharmacol Ther</i>, 1981, 29:480. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6781810\">[PubMed 6781810]</a></p>\n<p>6. Fernandez de gatta MR, Alonso Gonzalez AC, Garcia Sanchez MJ, et al, “Effect of Sodium Valproate on Phenobarbital Serum Levels in Children and Adults,” <i>Ther Drug Monit</i>, 1986, 8:416-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3103264\">[PubMed 3103264]</a></p>\n<p>7. Hurst SI, Hargreaves JA, Howald WN, et al, “Enzymatic Mechanism for the Phenobarbital-Valproate Interaction,” <i>Epilepsia</i>, 1997, 38(Suppl 8):111.</p>\n<p>8. Bernus I, Dickinson RG, Hooper WD, et al, “Inhibition of Phenobarbitone N-Glucosidation by Valproate,” <i>Br J Clin Pharmacol</i>, 1994, 38:411-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7893581\">[PubMed 7893581]</a></p>\n<p>9. Prescribing information. Depakote ER (divalproex). North Chicago, IL: Abbott Laboratories, March 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9545":"<p><b>Title</b> Valproate Products / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Valproate Products. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Doses of valproic acid and other valproate products may require adjustment when starting or stopping concurrent rifampin. Monitor plasma valproate concentrations closely and be aware of possible changes in clinical response that may be associated with changes in plasma concentration.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Concurrent rifampin (600mg daily x 5 days) has been reported to increase the clearance of valproate (single 7mg/kg dose) by 40%.<sup>1,2</sup><br><br>The suspected mechanism of this interaction is rifampin-mediated induction of valproate metabolism. Rifampin is a well-recognized inducer of several drug metabolizing enzymes, and valproate metabolism is primarily dependent on both glucuronidation (mediated by uridine diphosphate glucuronosyl transferase (UGT) enzymes) and mitochondrial beta-oxidation, with some minor involvement of CYP2C19 and CYP2C9.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bachmann KA, Jauregui L, “Use of Single Sample Clearance Estimates of Cytochrome P450 Substrates to Characterize Human Hepatic CYP Status In Vivo,” <i>Xenobiotica</i>, 1993, 23(3):307-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8498093\">[PubMed 8498093]</a></p>\n<p>2. Prescribing information. Depakote ER (divalproex). North Chicago, IL: Abbott Laboratories, 3/2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9546":"<p><b>Title</b> RisperiDONE / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may enhance the adverse/toxic effect of RisperiDONE. Generalized edema has developed. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for the development of peripheral edema during concomitant use of risperidone and valproic acid or other valproate products.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Two case reports describe the development of significant peripheral, dependent edema during concomitant treatment with risperidone and valproate.<sup>1,2</sup> The development of edema appeared to be risperidone dose-related (i.e. edema occurred with higher doses (e.g. 8 mg), but not with lower doses (e.g. 2 mg)), and recurred upon rechallenge. The edema was relatively unresponsive to diuretic therapy.<br><br>The mechanism of this possible interaction is unclear. Despite case reports suggesting possible increases<sup>4</sup> or decreases<sup>5</sup> in valproate concentrations during risperidone treatment, several additional cases<sup>6,7</sup> and a clinical study in 22 patients with bipolar disorder<sup>8</sup> identified no apparent pharmacokinetic interaction. Two clinical studies demonstrated no alterations in risperidone and 9-hydroxyrisperidone concentrations with valproate coadministration.<sup>9,10</sup> The described interaction is likely at best a rare occurrence, as numerous clinical trials investigating risperidone and valproate coadministration have failed to identify any additional cases of edema.<sup>9,11,12,13,14,15,16,17,18,19,20,21</sup><br><br>One case report describes hyperammonemia and manic symptoms developing in two children treated with risperidone and valproate.<sup>22</sup> However, preexisting psychological disorders, multiple additional medications, an absence of rechallenge data, and the lack of a plausible mechanism all cast doubts on the connection between these symptoms and a specific risperidone-valproate interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Baldassano CF and Ghaemi SN, “Generalized Edema with Risperidone: Divalproex Sodium Treatment,” <i>J Clin Psychiatry</i>, 1996, 57(9):422. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9746451\">[PubMed 9746451]</a></p>\n<p>2. Sanders RD and Lehrer DS, “Edema Associated with Addition of Risperidone to Valproate Treatment,” <i>J Clin Psychiatry</i>, 1998, 59(12):689-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9921707\">[PubMed 9921707]</a></p>\n<p>3. Carlson T, Reynolds CA and Caplan R, “Case Report: Valproic Acid and Risperidone Treatment Leading to Development of Hyperammonemia and Mania,” <i> J Am Acad Child Adolesc Psychiatry</i>, 2007, 46(3):356-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17314721\">[PubMed 17314721]</a></p>\n<p>4. van Wattum PJ, “Valproic Acid and Risperidone,” <i>J Am Acad Child Adolesc Psychiatry</i>, 2001, 40(8):866-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11501681\">[PubMed 11501681]</a></p>\n<p>5. Bertoldo M, “Valproic Acid and Risperidone,” <i> J Am Acad Child Adolesc Psychiatry</i>, 2002, 41(6):632. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12049437\">[PubMed 12049437]</a></p>\n<p>6. Sund JK, Aamo T and Spigset O, “Valproic Acid and Risperidone: A Drug Interaction?” <i>J Am Acad Child Adolesc Psychiatry</i>, 2003, 42(1):1-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12500067\">[PubMed 12500067]</a></p>\n<p>7. Good CR, Petersen CA and Krecko VF, “Valproic Acid and Risperidone,” <i>J Am Acad Child Adolesc Psychiatry</i>, 2003, 42(1):2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12500068\">[PubMed 12500068]</a></p>\n<p>8. Ravindran A, Silverstone P, Lacroix D, et al, “Risperidone Does Not Affect Steady-State Pharmacokinetics of Divalproex Sodium in Patients With Bipolar Disorder,” <i> Clin Pharmacokinet</i>, 2004, 43(11):733-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15301577\">[PubMed 15301577]</a></p>\n<p>9. Yoshimura R, Shinkai K, Ueda N, et al, “Valproic Acid Improves Psychotic Agitation Without Influencing Plasma Risperidone Levels in Schizophrenic Patients,” <i>Pharmacopsychiatry</i>, 2007, 40(1):9-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17327954\">[PubMed 17327954]</a></p>\n<p>10. Spina E, Avenoso A, Facciola G, et al, “Plasma Concentrations of Risperidone and 9-hydroxyrisperidone: Effect of Comedication with Carbamazepine or Valproate,” <i>Ther Drug Monit</i>, 2000, 22(4):481-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10942191\">[PubMed 10942191]</a></p>\n<p>11. Sachs GS, Grossman F, Ghaemi SN, et al, “Combination of a Mood Stabilizer With Risperidone or Haloperidol for Treatment of Acute Mania: A Double-Blind, Placebo-Controlled Comparison of Efficacy and Safety,” <i>Am J Psychiatry</i>, 2002 159(7):1146-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12091192\">[PubMed 12091192]</a></p>\n<p>12. Pavuluri MN, Henry DB, Carbray JA, et al, “Open-Label Prospective Trial of Risperidone in Combination With Lithium or Divalproex Sodium in Pediatric Mania,” <i> J Affect Disord</i>, 2004, 82 Suppl 1:S103-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15571784\">[PubMed 15571784]</a> </p>\n<p>13. Yatham LN, Grossman F, Augustyns I, et al, “Mood Stabilisers Plus Risperidone or Placebo in the Treatment of Acute Mania. International, Double-Blind, Randomised Controlled Trial,” <i>Br J Psychiatry</i>, 2003, 182:141-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12562742\">[PubMed 12562742]</a></p>\n<p>14. Yatham LN, Binder C, Kusumakar V, et al, “Risperidone Plus Lithium Versus Risperidone Plus Valproate in Acute and Continuation Treatment of Mania,” <i>Int Clin Psychopharmacol</i>, 2004, 19(2):103-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15076019\">[PubMed 15076019]</a></p>\n<p>15. Suzuki T, Uchida H, Takeuchi H, et al, “Augmentation of Atypical Antipsychotics With Valproic Acid. An Open-Label Study for Most Difficult Patients With Schizophrenia,” <i> Hum Psychopharmacol</i>, 2009, 24(8):628-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19946935\">[PubMed 19946935]</a></p>\n<p>16. Bowden CL, Myers JE, Grossman F, et al, “Risperidone in Combination With Mood Stabilizers: A 10-Week Continuation Phase Study in Bipolar I Disorder,” <i> J Clin Psychiatry</i>, 2004, 65(5):707-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15163260\">[PubMed 15163260]</a></p>\n<p>17. Bahk WM, Shin YC, Woo JM, et al, “Topiramate and Divalproex in Combination With Risperidone for Acute Mania: A Randomized Open-Label Study,” <i>Prog Neuropsychopharmacol Biol Psychiatry</i>, 2005, 29(1):115-21. Epub 2004 Nov 19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15610953\">[PubMed 15610953]</a></p>\n<p>18. Casey DE, Daniel DG, Tamminga C, et al, “Divalproex ER Combined With Olanzapine or Risperidone for Treatment of Acute Exacerbations of Schizophrenia,” <i>Neuropsychopharmacology</i>, 2009, 34(5):1330-8. Epub 2008 Dec 3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19052541\">[PubMed 19052541]</a></p>\n<p>19. Casey DE, Daniel DG, Wassef AA, et al, “Effect of Divalproex Combined With Olanzapine or Risperidone in Patients With an Acute Exacerbation of Schizophrenia,” <i> Neuropsychopharmacology</i>, 2003, 28(1):182-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12496955\">[PubMed 12496955]</a></p>\n<p>20. Citrome L, Casey DE, Daniel DG, et al, “Adjunctive Divalproex and Hostility Among Patients With Schizophrenia Receiving Olanzapine or Risperidone,” <i>Psychiatr Serv</i>, 2004, 55(3):290-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15001730\">[PubMed 15001730]</a> </p>\n<p>21. Citrome L, Shope CB, Nolan KA, et al, “Risperidone Alone Versus Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility,” <i>Int Clin Psychopharmacol</i>, 2007, 22(6):356-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17917554\">[PubMed 17917554]</a></p>\n<p>22. Carlson T, Reynolds CA and Caplan R, “Case Report: Valproic Acid and Risperidone Treatment Leading to Development of Hyperammonemia and Mania,” <i> J Am Acad Child Adolesc Psychiatry</i>, 2007, 46(3):356-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17314721\">[PubMed 17314721]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9547":"<p><b>Title</b> Rufinamide / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Valproate Products may increase the serum concentration of Rufinamide. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Initiate rufinamide at a dose less than 10 mg/kg/day (children) or 400 mg/day (adults) in patients receiving valproic acid or other other valproate products. In patients receiving rufinamide, initiate valproate products at a low dose and titrate based on clinical response. Monitor for increased rufinamide concentrations/effects with valproate initiation/dose increase, or decreased concentrations/effects with valproate discontinuation/dose decrease.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> According to rufinamide prescribing information, concomitant use of rufinamide with valproate was associated with increased rufinamide serum concentrations (from less than 16%, up to 70%, dependent on valproate dose).<sup>1</sup> Several additional studies have demonstrated increased average rufinamide concentrations/exposure or decreased rufinamide dose requirements during valproate treatment.<sup>2,3,4,5</sup> The mechanism of this apparent interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Banzel (rufinamide). Woodcliff Lake, NJ: Eisai Inc., March 2011.</p>\n<p>2. May TW, Boor R, Rambeck B, et al, “Serum Concentrations of Rufinamide in Children and Adults With Epilepsy: The Influence of Dose, Age, and Comedication,” <i>Ther Drug Monit</i>, 2011. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21383651\">[PubMed 21383651]</a></p>\n<p>3. Marchand M, Fuseau E and Critchley DJ, “Supporting the Recommended Paediatric Dosing Regimen for Rufinamide in Lennox-Gastaut Syndrome Using Clinical Trial Simulation,” <i>J Pharmacokinet Pharmacodyn</i>, 2010, 37(1):99-118. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20084538\">[PubMed 20084538]</a></p>\n<p>4. Coppola G, Grosso S, Franzoni E, et al, “Rufinamide in Children and Adults With Lennox-Gastaut Syndrome: First Italian Multicenter Experience,” <i>Seizure</i>, 2010, 19(9):587-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20888268\">[PubMed 20888268]</a></p>\n<p>5. Perucca E, Cloyd J, Critchley D, et al, “Rufinamide: Clinical Pharmacokinetics and Concentration-Response Relationships in Patients With Epilepsy,” <i>Epilepsia</i>, 2008, 49(7):1123-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18503564\">[PubMed 18503564]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9548":"<p><b>Title</b> Valproate Products / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Salicylates may increase the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicity of valproic acid and other valproate products if a salicylate is initiated/dose increased, and decreased effects if a salicylate is discontinued/dose decreased.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> At least 3 cases have been published describing acute valproate-associated toxicity in children following the addition of aspirin their therapy.<sup>1</sup> A fourth case demonstrates a possible relationship between these drugs in the development of hyperammonemia.<sup>2</sup> Aspirin has been shown to increase the unbound serum concentration of valproate.<sup>3,4</sup> This may be be, at least partially, responsible for the effects observed in these case reports.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Goulden KJ, Dooley JM, Camfield PR, et al, “Clinical Valproate Toxicity Induced by Acetylsalicylic Acid,” <i>Neurology</i>, 1987, 37(8):1392-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3112611\">[PubMed 3112611]</a></p>\n<p>2. Ichikawa H, Amano T, Kawabata K, et al, “Fatal Hyperammonemia in a Patient with Systemic Lupus Erythematosus,” <i>Intern Med</i>, 1998, 37(8):700-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9745859\">[PubMed 9745859]</a></p>\n<p>3. Orr JM, Abbott FS, Farrell K, et al, “Interaction Between Valproic Acid and Aspirin in Epileptic Children: Serum Protein Binding and Metabolic Effects,” <i>Clin Pharmacol Ther</i>, 1982, 31(5):642-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6804150\">[PubMed 6804150]</a></p>\n<p>4. Abbott FS, Kassam J, Orr JM, et al, “The Effect of Aspirin on Valproic Acid Metabolism,” <i>Clin Pharmacol Ther</i>, 1986, 40(1):94-100. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3087680\">[PubMed 3087680]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9549":"<p><b>Title</b> Sodium Oxybate / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Valproate Products may increase the serum concentration of Sodium Oxybate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider a sodium oxybate dose reduction of at least 20% if combined with valproic acid.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the prescribing information, sodium oxybate (6 g per day as 3 g four hours apart) administered with divalproex sodium (valproic acid 1250 mg/day) resulted in a 25% increase in the AUC of sodium oxybate. The maximum serum concentration (C<sub>max</sub>) of sodium oxybate was unchanged. No changes in the pharmacokinetics of valproic acid were seen. Greater impairment on tests of attention and working memory was also observed with co-administration of both agents than with either drug alone.<sup>1</sup> The manufacturer recommends that the dose of sodium oxybate be decreased by at least 20% if co-administered with valproic acid.<sup>1</sup><br><br>The proposed mechanism for this pharmacokinetic interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Xyrem</i> (sodium oxybate) [prescribing information]. Palo Alto, CA, Jazz Pharmaceuticals, Inc; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9550":"<p><b>Title</b> Temozolomide / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may enhance the adverse/toxic effect of Temozolomide. Valproate Products may increase the serum concentration of Temozolomide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase monitoring for signs or symptoms of temozolomide toxicity (particularly hematologic toxicity and hepatotoxicity) when used concurrently with valproic acid or other valproate products.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> A case report describes hepatotoxicity (acute cholestatic hepatitis with hepatic failure) in a patient with glioblastoma who had been receiving valproic acid and was treated with temozolomide and cilengitide.<sup>1</sup> After discontinuation of both valproic acid and temozolomide, liver function tests returned to baseline values. Temozolomide was later restarted without incident. A retrospective study of patients with glioblastoma (about 35% of whom were receiving temozolomide) noted that patients receiving non-enzyme-inducing antiepileptic drugs (primarily valproic acid) demonstrated both improved survival and greater hematologic toxicity as compared to those patients receiving enzyme-inducing antiepileptic drugs.<sup>2</sup> The authors proposed that this difference could result from the lack of enzyme induction in the primarily valproic acid group or enzyme inhibition by valproate (i.e., increased chemotherapeutic agent concentrations and effects) or some combination of these effects. According to temozolomide prescribing information, temozolomide oral clearance is an average of 5% lower with concurrent valproic acid,<sup>3</sup> though the prescribing information notes that the clinical significance of such an effect is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Neyns B, Hoorens A,Stupp R, “Valproic Acid Related Idiosyncratic Drug Induced Hepatotoxicity in a Glioblastoma Patient Treated with Temozolomide,” <i>Acta Neurol Belg</i>, 2008, 108:131-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19239041\">[PubMed 19239041]</a></p>\n<p>2. Oberndorfer S, Piribauer M, Marosi C, et al, “P450 Enzyme Inducing and Non-Enzyme Inducing Antiepileptics in Glioblastoma Patients Treated with Standard Chemotherapy,” <i>J Neurooncol</i>, 2005, 72:255-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15937649\">[PubMed 15937649]</a></p>\n<p>3. Prescribing information. Temodar (temozolomide). Kenilworth, NJ: Schering Corp., May 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9551":"<p><b>Title</b> Valproate Products / Topiramate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Topiramate may enhance the adverse/toxic effect of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for the development of adverse reactions including encephalopathy (with or without hyperammonemia), hepatic dysfunction, and hypothermia during concomitant use of topiramate and valproic acid or other valproate products.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Case reports describe development adverse reactions including encephalopathy (with or without hyperammonemia),<sup>1,2,3,4,5,6,7</sup> hepatic dysfunction/failure,<sup>7,8</sup> and hypothermia<sup>7,9</sup> in patients receiving valproate and topiramate concomitantly. Topiramate prescribing information contains a warning regarding development of hypothermia and associated symptoms (lethargy, confusion, coma, abnormal function of major organ systems) in patients receiving this combination.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Latour P, Biraben A, Polard E, et al, “Drug Induced Encephalopathy in Six Epileptic Patients: Topiramate? Valproate? Or Both?,” <i>Hum Psychopharmacol</i>, 2004, 19(3):193-203. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15079854\">[PubMed 15079854]</a></p>\n<p>2. Hamer HM, Knake S, Schomburg U, et al, “Valproate-Induced Hyperammonemic Encephalopathy in the Presence of Topiramate,” <i>Neurology</i>, 2000, 54(1):230-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10636156\">[PubMed 10636156]</a></p>\n<p>3. Solomon GE, “Valproate-Induced Hyperammonemic Encephalopathy in the Presence of Topiramate,” <i>Neurology</i>, 2000, 55(4):606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10953214\">[PubMed 10953214]</a></p>\n<p>4. Cheung E, Wong V and Fung CW, “Topiramate-Valproate-Induced Hyperammonemic Encephalopathy Syndrome: Case Report,” <i>J Child Neurol</i>, 2005, 20(2):157-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15794187\">[PubMed 15794187]</a></p>\n<p>5. Panda S and Radhakrishnan K, “Two Cases of Valproate-Induced Hyperammonemic Encephalopathy Without Hepatic Failure,” <i>J Assoc Physicians India</i>, 2004, 52:746-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15839456\">[PubMed 15839456]</a></p>\n<p>6. Deutsch SI, Burket JA and Rosse RB, “Valproate-Induced Hyperammonemic Encephalopathy and Normal Liver Functions: Possible Synergism With Topiramate,” <i>Clin Neuropharmacol</i>, 2009, 32(6):350-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19952878\">[PubMed 19952878]</a></p>\n<p>7. Longin E, Teich M, Koelfen W, et al, “Topiramate Enhances the Risk of Valproate-Associated Side Effects in Three Children,” <i>Epilepsia</i>, 2002, 43(4):451-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11952778\">[PubMed 11952778]</a></p>\n<p>8. Bumb A, Diederich N, and Beyenburg S, “Adding Topiramate to Valproate Therapy May Cause Reversible Hepatic Failure,” <i>Epileptic Disord</i>, 2003, 5(3):157-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14684351\">[PubMed 14684351]</a></p>\n<p>9. Knudsen JF, Sokol GH, and Flowers CM, “Adjunctive Topiramate Enhances the Risk of Hypothermia Associated With Valproic Acid Therapy,” <i>J Clin Pharm Ther</i>, 2008, 33(5):513-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18834366\">[PubMed 18834366]</a></p>\n<p>10. Prescribing information. Topamax (topiramate). Titusville, NJ: Janssen Pharmaceuticals, Inc., July 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9552":"<p><b>Title</b> Valproate Products / Trihexyphenidyl</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trihexyphenidyl may decrease the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Consider monitoring for decreased valproate serum concentrations in patients receiving trihexyphenidyl.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> A single case report describes a 3 year old patient who experienced loss of seizure control and an apparent decrease in valproate (sodium valproate 30 mg/kg/day enterally) serum concentrations approximately 3 months after initiation of trihexyphenidyl (0.5 mg daily enterally).<sup>1</sup> Sodium valproate doses were subsequently increased to 45 mg/kg/day but seizure control remained poor and serum concentrations remained below therapeutic target concentrations at 48 ug/mL. Trihexyphenidyl was discontinued, and valproate concentrations rose to 74 ug/mL without further sodium valproate dose escalation. <br><br>The mechanism of this possible interaction is unknown. It is also unknown whether it may occur systemically or in the gastrointestinal tract (in the latter case it may apply only to sodium valproate and not to other salts or formulations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. De Rinaldis M, Gennaro L, Losito L, et al, “Drug-to-Drug Interaction Between Sodium Valproate and Trihexyphenidyl in a Child With Extrapyramidal Cerebral Palsy and Epilepsy,” <i>Eur J Clin Pharmacol</i>, 2010 Oct 20. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20959970\">[PubMed 20959970]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9553":"<p><b>Title</b> Urea Cycle Disorder Agents / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Valproate Products may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Enhanced plasma ammonia monitoring may be required to guide dose titration of phenylbutyrate products following initiation or dose modification of valproic acid or other valproate products.</p>\n<div>\n <p><b>Urea Cycle Disorder Agents Interacting Members</b> Glycerol Phenylbutyrate, Sodium Phenylbutyrate</p>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> According to U.S. prescribing information for sodium phenylbutyrate and glycerol phenylbutyrate products, caution may be warranted with coadministration of agents such as valproate or haloperidol that have been associated with hyperammonemia.<sup>1,2</sup> Enhanced monitoring of ammonia concentrations may be necessary to guide appropriate phenylbutyrate dose adjustment following initiation or dose modification of these drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ravicti (glycerol phenylbutyrate). South San Francisco, CA: Hyperion Therapeutics Inc., February 2013.</p>\n<p>2. Prescribing information. Buphenyl (sodium phenylbutyrate). Scottsdale, AZ: Ucyclyd Pharma, Inc., 2/2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9554":"<p><b>Title</b> Vorinostat / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may enhance the thrombocytopenic effect of Vorinostat. This may increase the risk of gastrointestinal bleeding. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor CBC with differential for exaggerated thrombocytopenia if concomitant therapy is employed. The manufacturer of vorinostat recommends monitoring of platelet counts every 2 weeks for the first 2 months of vorinostat treatment, and this same schedule is recommended with concomitant therapy. Additional assessments should include observing for signs and symptoms of abnormal bleeding, particularly in the gastrointestinal tract.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> The manufacturer of vorinostat reports the occurrence of severe hematologic toxicity (thrombocytopenia) and gastrointestinal bleeding when vorinostat is administered with other histone deacetylation inhibitors such as valproic acid.<sup>1</sup> The mechanism of this interaction is unknown, and the number of patients affected is undisclosed. Careful monitoring is recommended.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zolinza (vorinostat). Whitehouse Station, NJ: Merck &amp; Co, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9555":"<p><b>Title</b> Warfarin / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Valproate Products may decrease the protein binding of Warfarin. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Free warfarin concentrations were increased approximately 32% in the presence of valproate, due to a reduction in serum protein binding, in an in vitro study.<sup>1</sup> To date, no clinically-relevant interactions between these drugs have been identified. A 2002 paper by Benet<sup>2</sup> quite definitively demonstrated that protein binding displacement has very little effect on drug exposure, except for drugs with high liver extraction ratios administered via a non-oral route. Warfarin does not fit this profile.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Guthrie SK, Stoysich AM, Bader G, et al, “Hypothesized Interaction Between Valproic Acid and Warfarin,” <i>J Clin Psychopharmacol</i>, 1995, 15(2):138-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7782487\">[PubMed 7782487]</a></p>\n<p>2. Benet LZ and Hoener B, “Changes in Plasma Protein Binding Have Little Clinical Relevance,” <i>Clin Pharmacol Therapeut</i>, 2002, 71(3):115-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11907485\">[PubMed 11907485]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9556":"<p><b>Title</b> Zidovudine / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may increase the serum concentration of Zidovudine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased zidovudine concentrations/toxicity (e.g., hematologic) if valproic acid or other valproate products are initiated/dose increased.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> The AUC of zidovudine (100 mg every 8 hours) was increased 80% in 6 normal subjects when coadministered with valproic acid (250 mg every 8 hours) for 4 days.<sup>1</sup> <i>In vitro</i> data demonstrate that valproate can inhibit the uridine-5'-diphospho-glucuronosyltransferase (UGT) enzyme metabolism of zidovudine at clinically achievable serum concentrations.<sup>2,3</sup> A case report demonstrates a nearly threefold increase in zidovudine CSF concentrations following the addition of valproic acid.<sup>4</sup> Another case report describes the development of anemia in a patient receiving zidovudine (along with a number of other drugs) following the addition of valproic acid. The anemia was believed to be the result of zidovudine toxicity caused by a drug-induced reduction in metabolism by valproate.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lertora JJ, Rege AB, Greenspan DL, et al, “Pharmacokinetic Interaction Between Zidovudine and Valproic Acid in Patients Infected With Human Immunodeficiency Virus,” <i>Clin Pharmacol Ther</i>, 1994, 56(3):272-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7924122\">[PubMed 7924122]</a></p>\n<p>2. Trapnell CB, Kleckner RW, Jamis-Dow C, et al, “Glucuronidation of 3'-Azido-3'-Deoxythymidine (Zidovudine) by Human Liver Microsomes: Relevance to Clinical Phamacokinetic Interactions With Atovaquone, Fluconazole, Methadone, and Valproic Acid,” <i>Antimicrob Agents Chemother</i>, 1998, 42(7):1592-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9660989\">[PubMed 9660989]</a></p>\n<p>3. Rajaonarison JF, Lacarelle B, Catalin J, et al, “3'-Azido-3'-Deoxythymidine Drug Interactions: Screening For Inhibitors in Human Liver Microsomes,” <i>Drug Metab Disp</i>, 1992, 20(4):578-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1356738\">[PubMed 1356738]</a></p>\n<p>4. Akula SK, Rege AB, Dreisback AW, et al, “Valproic Acid Increases Cerebrospinal Fluid Zidovudine Levels in a Patient With AIDS,” <i>Am J Med Sci</i>, 1997, 313(4):244-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9099156\">[PubMed 9099156]</a></p>\n<p>5. Antoniou T, Gough K, Yoong D, et al, “Severe Anemia Secondary to a Probable Drug Interaction Between Zidovudine and Valproic Acid,” <i>Clin Infec Dis</i>, 2004, 38:e38-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14986271\">[PubMed 14986271]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9557":"<p><b>Title</b> Daclatasvir / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Daclatasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of daclatasvir and strong CYP3A4 inducers. This combination is specifically listed as a contraindication in the daclatasvir prescribing information.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the daclatasvir prescribing information, the strong CYP3A4 inducer rifampin (600 mg daily) decreased the daclatasvir (60 mg single dose) AUC and maximum serum concentration 79% and 56%, respectively.<sup>1</sup><br><br>Daclatasvir prescribing information states that concomitant use of daclatasvir and a strong CYP3A4 inducer may lead to decreased daclatasvir concentrations, loss of virologic response, and possible development of resistance.<sup>1</sup> The use of strong CYP3A4 inducers with daclatasvir is contraindicated.<sup>1</sup><br><br>The mechanism of this interaction is likely increased CYP3A4-mediated metabolism of daclatasvir due to induction of CYP3A4 by strong CYP3A4 inducers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daklinza (daclatasvir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9558":"<p><b>Title</b> Daclatasvir / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daclatasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase the daclatasvir dose to 90 mg once daily if used with a moderate CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 17 healthy volunteers, daclatasvir pharmacokinetic parameters were evaluated after 4 days of daclatasvir 60 mg daily and after daclatasvir 120 mg daily combined with the moderate CYP3A4 inducer efavirenz 600 mg daily (efavirenz was administered for 14 days and the increased daclatasvir dose was administered for 4 days).<sup>1</sup> Daclatasvir AUC and maximum serum concentration were 37% and 67% higher, respectively, when high-dose daclatasvir combined with efavirenz was compared with standard-dose daclatasvir alone.<sup>1</sup> Linear dose scaling projected that use of efavirenz (or other moderate CYP3A4 inducers) with daclatasvir 90 mg daily would result in an AUC similar to that of daclatasvir 60 mg daily alone.<sup>1</sup><br><br>Daclatasvir prescribing information states that concomitant use of daclatasvir and CYP3A4 inducers may lead to decreased daclatasvir concentrations, loss of virologic response, and possible development of resistance.<sup>2</sup> The dose of daclatasvir should be increased to 90 mg once daily if combined with a moderate CYP3A4 inducer.<sup>2</sup><br><br>The mechanism of this interaction is likely CYP3A4 induction, an enzyme responsible for the majority of daclatasvir metabolism, by CYP3A4 inducers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. <i>Antivir Ther</i>. 2013;18(7):931-940. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23963204\">[PubMed 23963204]</a></p>\n<p>2. Daklinza (daclatasvir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9559":"<p><b>Title</b> Daclatasvir / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Daclatasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of daclatasvir and St Johns wort. This combination is specifically listed as a contraindication in the daclatasvir prescribing information.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the daclatasvir prescribing information, the strong CYP3A4 inducer rifampin (600 mg daily) decreased the daclatasvir (60 mg single dose) AUC and maximum serum concentration 79% and 56%, respectively.<sup>1</sup><br><br>Daclatasvir prescribing information states that concomitant use of daclatasvir and CYP3A4 inducers, including St Johns wort, may lead to decreased daclatasvir concentrations, loss of virologic response, and possible development of resistance.<sup>1</sup> The use of St Johns wort with daclatasvir is contraindicated.<sup>1</sup><br><br>The mechanism of this potential interaction is induction of CYP3A4, an enzyme responsible for the majority of daclatasvir metabolism, by St Johns wort.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daklinza (daclatasvir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9560":"<p><b>Title</b> Daclatasvir / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Daclatasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Decrease the daclatasvir dose to 30 mg once daily if combined with a strong CYP3A4 inhibitor. No dose adjustment is needed when daclatasvir is used with darunavir/cobicistat.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the daclatasvir prescribing information, ketoconazole (400 mg daily) increased the daclatasvir (10 mg single dose) AUC and maximum serum concentration (Cmax) 3-fold and 1.6-fold, respectively.<sup>1</sup> In another pharmacokinetic study of 14 healthy volunteers, daclatasvir pharmacokinetic parameters were evaluated after 4 days of daclatasvir 60 mg daily and after 10 days of daclatasvir 20 mg daily combined with the strong CYP3A4 inhibitor atazanavir/ritonavir (300 mg/100 mg daily).<sup>2</sup> Daclatasvir AUC and Cmax were 30% and 55% lower, respectively, when low-dose daclatasvir combined with atazanavir/ritonavir was compared with standard-dose daclatasvir alone.<sup>2</sup> Linear dose scaling projected that use of atazanavir/ritonavir (or other strong CYP3A4 inhibitors) with daclatasvir 30 mg daily would result in an AUC similar to that of daclatasvir 60 mg daily alone.<sup>2</sup><br><br>Prescribing information for daclatasvir states that use of strong CYP3A4 inhibitors with daclatasvir may result in increased daclatasvir concentrations and a greater risk for adverse events.<sup>1</sup> The dose of daclatasvir should be reduced to 30 mg once daily if combined with a strong CYP3A4 inhibitor, except that no dose adjustment is needed if daclatasvir is used with darunavir/cobicistat.<sup>1</sup><br><br>The mechanism of this interaction is likely CYP3A4 inhibition by CYP3A4 inhibitors, an enzyme responsible for the majority of daclatasvir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daklinza (daclatasvir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; February 2016.</p>\n<p>2. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. <i>Antivir Ther</i>. 2013;18(7):931-940. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23963204\">[PubMed 23963204]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9561":"<p><b>Title</b> Digoxin / Daclatasvir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Daclatasvir may increase the serum concentration of Digoxin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> <u>In patients taking daclatasvir who are started on digoxin</u>: Begin digoxin treatment using the lowest appropriate digoxin dose. Monitor digoxin concentrations and adjust the digoxin dose as necessary.<br><br><u>In patients taking digoxin who are started on daclatasvir</u>: Measure digoxin concentrations before initiating daclatasvir. Decrease the digoxin dose by 15% to 30% or by modifying the digoxin dosing frequency (e.g., extend the dosing interval) and continue monitoring digoxin serum concentrations.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the daclatasvir prescribing information, daclatasvir (60 mg daily) increased the digoxin (0.125 mg daily) AUC, maximum serum concentration, and minimum serum concentration 27%, 65%, and 18%, respectively.<sup>1</sup><br><br>The mechanism for this interaction is likely daclatasvir inhibition of P-glycoprotein, a transporter responsible for digoxin disposition.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Daklinza (daclatasvir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9562":"<p><b>Title</b> Sonidegib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sonidegib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of sonidegib and strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in sonidegib US prescribing information, coadministration of ketoconazole (200 mg orally twice daily) increased the sonidegib (800 mg single oral dose) maximum concentration and AUC by 1.5- and 2.2-fold, respectively, in healthy volunteers.<sup>1</sup> The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4-mediated sonidegib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Odomzo (sonidegib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9563":"<p><b>Title</b> Sonidegib / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible. When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for evidence of sonidegib toxicity (particularly musculoskeletal adverse reactions).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in sonidegib US prescribing information, coadministration of the strong CYP3A4 inhibitor ketoconazole (200 mg orally twice daily) increased the sonidegib (800 mg single oral dose) maximum concentration and AUC by 1.5- and 2.2-fold, respectively, in healthy volunteers.<sup>1</sup> Based on simulations, the moderate CYP3A4 inhibitor erythromycin may increase the steady-state sonidegib AUC by 1.8-fold when coadministered for 14 days and by 2.8-fold when coadministered for 4 months.<br><br>The suspected primary mechanism of this interaction is inhibition of CYP3A4-mediated sonidegib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Odomzo (sonidegib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9564":"<p><b>Title</b> Sonidegib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Sonidegib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of sonidegib and strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in sonidegib US prescribing information, coadministration of rifampin (600 mg orally daily) decreased the sonidegib (800 mg single oral dose) maximum concentration and AUC by 54% and 72%, respectively, in healthy volunteers.<sup>1</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4-mediated sonidegib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Odomzo (sonidegib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9565":"<p><b>Title</b> Sonidegib / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sonidegib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of sonidegib and moderate CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in sonidegib US prescribing information, coadministration of rifampin (600 mg orally daily) decreased the sonidegib (800 mg single oral dose) maximum concentration and AUC by 54% and 72%, respectively, in healthy volunteers.<sup>1</sup> Based on simulations, the moderate CYP3A4 inducer efavirenz may decrease the steady-state sonidegib AUC by 56% when coadministered for 14 days and by 69% when coadministered for 4 months.<br><br>The suspected primary mechanism of this interaction is induction of CYP3A4-mediated sonidegib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Odomzo (sonidegib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9566":"<p><b>Title</b> Amiodarone / Daclatasvir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Daclatasvir may enhance the bradycardic effect of Amiodarone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the combination of sofosbuvir, daclatasvir, and amiodarone. Serious symptomatic bradycardia has been reported with this combination. <br><br>For patients where there are no viable treatment alternatives and this combination must be used, the manufacturer recommends cardiac monitoring in an in-patient setting for the first 48 hours of coadministration. Outpatient or self-monitoring of heart rate should occur daily through at least the first 2 weeks of treatment and patients should be counseled about the risk of serious symptomatic bradycardia. Due to the long half-life of amiodarone, patients who discontinue amiodarone just prior to starting sofosbuvir and daclatasvir should also undergo similar cardiac monitoring.</p> \n<p><b>Discussion</b> According to the prescribing information for daclatasvir and sofosbuvir products, postmarketing cases of symptomatic bradycardia, cases requiring pacemaker insertion, as well as one fatal cardiac arrest, have been reported in patients taking amiodarone with sofosbuvir and a direct-acting antiviral (eg, ledipasvir, simeprevir, daclatasvir).<sup>1,2,3</sup> Bradycardia has generally occurred within hours to days, but cases have been observed up to 2 weeks after initiating sofosbuvir containing treatment regimens. Patients taking beta blockers or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk. Bradycardia generally resolved after discontinuation of the sofosbuvir containing treatment regimen. <br><br>The mechanism of this observed effect is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Solvadi (sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2015.</p>\n<p>2. Harvoni (sofosbuvir/ledipasvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2015.</p>\n<p>3. Daklinza (daclatasvir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9567":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Daclatasvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Daclatasvir may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased HMG-CoA reductase inhibitor (statin) toxicities (eg, myopathy) if combined with daclatasvir.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the daclatasvir prescribing information, daclatasvir (60 mg daily) increased the rosuvastatin (10 mg single dose) AUC and maximum serum concentration 1.6-fold and 2.0-fold, respectively.<sup>1</sup><br><br>The proposed mechanism of this interaction is daclatasvir inhibition of OATP/SLCO1B1, OATP/SLCO1B3, and breast cancer resistance protein (BCRP), which are all transporters involved in rosuvastatin hepatic uptake or elimination.<sup>1,2,3</sup> Since all statins rely on OATP/SLCO transporters for hepatic uptake (at least partially), prescribing information for daclatasvir states that the combination of daclatasvir and any statin may result in increased statin exposure and toxicities.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Daklinza (daclatasvir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2015.</p>\n<p>2. Furihata T, Matsumoto S, Fu Z, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. <i>Antimicrob Agents Chemother</i>. 2014;58(8):4555-4564. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24867984\">[PubMed 24867984]</a></p>\n<p>3. Crestor (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9568":"<p><b>Title</b> Vindesine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vindesine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased vindesine toxicities if combined with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> One report describes 2 patients who experienced increases in vindesine adverse events (eg, paralytic ileus, limb paresthesias) after itraconazole was added to their vindesin- containing chemotherapy regimens.<sup>1</sup> <br><br>Product labeling for vindesine states that concomitant administration of vindesine and a CYP3A4 inhibitor may result in decreased vindesine metabolism and earlier onset and/or an<br>increased severity of adverse events.<sup>2</sup><br><br>Although this interaction has not been fully investigated, strong CYP3A4 inhibitors (eg, itraconazole) inhibit CYP3A4, an enzyme responsible for vindesine metabolism.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chen S, Wu D, Sun A, et al. Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia. <i>Am J Hematol</i>. 2007;82(10):942. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17617780\">[PubMed 17617780]</a></p>\n<p>2. Eldisine (vindesine) [summary of product characteristics]. Linthwaite, Huddersfield, UK: Genus Pharmaceuticals Limited; June 2014.</p>\n<p>3. Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. <i>Biochem Pharmacol</i>. 1993;45(4):853-861. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8452560\">[PubMed 8452560]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9569":"<p><b>Title</b> Phenytoin / Vindesine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vindesine may decrease the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased phenytoin levels and decreased phenytoin efficacy if combined with vindesine.</p> \n<p><b>Discussion</b> Case reports describe reductions in phenytoin levels and breakthrough seizure activity in patients treated with vincristine or vinblastine combined with numerous cytotoxic chemotherapy agents (eg, bleomycin, carmustine, cisplatin, daunorubicin, methotrexate).<sup>1,2,3</sup><br><br>Product labeling for vindesine states that antineoplastic chemotherapy combinations that include vinca alkaloids have resulted in reduced blood levels of phenytoin and increased seizure activity. Although the contribution of vinca alkaloids has not been established, dosage adjustment of phenytoin may be needed when used in combination with vindesine.<sup>4</sup><br><br>The mechanism of this potential interaction is unclear, but reduced phenytoin absorption due to chemotherapy-induced GI mucosal damage has been proposed.<sup>1,2,3</sup> The role of vinca alkaloids in this interaction is uncertain due to the use of multiple medications.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bollini P, Riva R, Albani F, et al. Decreased phenytoin level during antineoplastic therapy: a case report. <i>Epilepsia</i>. 1983;24(1):75-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6822234\">[PubMed 6822234]</a></p>\n<p>2. Sylvester RK, Lewis FB, Caldwell KC, Lobell M, Perri R, Sawchuk RA. Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine, and bleomycin. <i>Ther Drug Monit</i>. 1984;6(3):302-305. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6209833\">[PubMed 6209833]</a></p>\n<p>3. Jarosinski PF, Moscow JA, Alexander MS, Lesko LJ, Balis FM, Poplack DG. Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia. <i>J Pediatr</i>. 1988;112(6):996-999. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3163735\">[PubMed 3163735]</a></p>\n<p>4. Eldisine (vindesine) [summary of product characteristics]. Linthwaite, Huddersfield, UK: Genus Pharmaceuticals Limited; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9570":"<p><b>Title</b> Vindesine / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased vindesine toxicities if combined with a moderate CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil<br><b>Exception</b> Grapefruit Juice</p>\n</div> \n<p><b>Discussion</b> One report describes 2 patients who experienced increases in vindesine adverse events (eg, paralytic ileus, limb paresthesias) after the strong CYP3A4 inhibitor itraconazole was added to their vindesine-containing chemotherapy regimens.<sup>1</sup> <br><br>Product labeling for vindesine states that concomitant administration of vindesine and a CYP3A4 inhibitor may result in decreased vindesine metabolism and earlier onset and/or an<br>increased severity of adverse events.<sup>2</sup><br><br>Although this interaction has not been fully investigated, inhibition of CYP3A4, an enzyme responsible for vindesine metabolism, by CYP3A4 inhibitors, is likely responsible.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chen S, Wu D, Sun A, et al. Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia. <i>Am J Hematol</i>. 2007;82(10):942. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17617780\">[PubMed 17617780]</a></p>\n<p>2. Eldisine (vindesine) [summary of product characteristics]. Linthwaite, Huddersfield, UK: Genus Pharmaceuticals Limited; June 2014.</p>\n<p>3. Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. <i>Biochem Pharmacol</i>. 1993;45(4):853-861. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8452560\">[PubMed 8452560]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}